




ACADEMIA ESPAÑOLA
DE DERMATOLOGÍA
Y VENEREOLOGÍA

ACTAS Dermo-Sifiliográficas

Full English text available at
www.actasdermo.org



CONSENSUS DOCUMENT

[Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2—Management of Special Populations, Patients With Comorbid Conditions, and Risk

J.M. Carrascosa^{a,*}, L. Puig^b, I.B. Romero^c, L. Salgado-Boquete^d, E. del Alcázar^a, J.J.A. Lencina^e, D. Moreno^f, P. de la Cueva^g

^a Departamento de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, IGTP, Barcelona, Spain

^b Departamento de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

^c Departamento de Dermatología, Hospital General Universitario de Alicante-ISABIAL – Universidad Miguel Hernández de Elche, Alicante, Spain

^d Departamento de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain

^e Servicio de Dermatología, Hospital Universitario Vega Baja, Alicante, Spain

^f Departamento de Dermatología, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Sevilla, Spain

^g Servicio de Dermatología, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain

Received 11 January 2022; accepted 26 January 2022

Available online 21 May 2022

KEYWORDS

Psoriasis;
Biologic therapy;
Recommendations;
Guidelines

Abstract

Background and objectives: Since its inception, the Psoriasis Group (GPs) of the Spanish Academy of Dermatology and Venereology (AEDV) has worked to continuously update recommendations for the treatment of psoriasis based on the best available evidence and incorporating proposals arising from and aimed at clinical practice. An updated GPs consensus document on the treatment of moderate to severe psoriasis was needed because of changes in the treatment paradigm and the approval in recent years of a large number of new biologic agents.

DOI of original article: <https://doi.org/10.1016/j.ad.2022.01.024>

* Corresponding author.

E-mail address: jmcarrascosac.germanstrias@gencat.cat (J.M. Carrascosa).

<https://doi.org/10.1016/j.ad.2022.01.040>

0001-7310/© 2022 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Methodology: The consensus document was developed using the nominal group technique complemented by a scoping review. First, a designated coordinator selected a group of GPs members for the panel based on their experience and knowledge of psoriasis. The coordinator defined the objectives and key points for the document and, with the help of a documentalist, conducted a scoping review of articles in Medline, Embase, and the Cochrane Library up to January 2021. The review included systematic reviews and meta-analyses as well as clinical trials not included in those studies and high-quality real-world studies. National and international clinical practice guidelines and consensus documents on the management of moderate to severe psoriasis were also reviewed. The coordinator then drew up a set of proposed recommendations, which were discussed and modified in a nominal group meeting. After several review processes, including external review by other GPs members, the final document was drafted.

Results: The present guidelines include updated recommendations on assessing the severity of psoriasis and criteria for the indication of systemic treatment. They also include general principles for the treatment of patients with moderate to severe psoriasis and define treatment goals for these patients as well as criteria for the indication and selection of initial and subsequent therapies. Practical issues, such as treatment failure and maintenance of response, are also addressed.

© 2022 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Psoriasis;
Terapia biológica;
Recomendaciones;
Guía

Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo»

Resumen

Justificación y objetivos: El desarrollo del actual arsenal terapéutico fundamentado en las terapias biológicas, la experiencia acumulada en ensayos clínicos y en práctica clínica real y los nuevos conocimientos sobre la patogénesis en psoriasis permiten posibilidades de individualización y hacen adecuada una actualización de las recomendaciones en cuanto a la gestión del riesgo en pacientes tratados con estos fármacos.

El Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) trabaja desde su creación en la actualización continua de las recomendaciones para el tratamiento de la psoriasis, basándose en la mejor evidencia disponible e incorporando propuestas orientadas desde y para la práctica clínica.

Metodología: Para la elaboración del consenso se siguió la metodología de grupos nominales, con ayuda de una *scoping review*. Tras designar a un coordinador, se seleccionó un grupo de trabajo constituido por integrantes del GPS con base en su experiencia y conocimiento en psoriasis. El coordinador definió los objetivos y puntos clave del documento y con ayuda de un documentalista se realizó una *scoping review* incluyendo datos de Medline, Embase y Cochrane Library (hasta enero del 2021). Se seleccionaron revisiones sistemáticas, metaanálisis y ensayos clínicos no incluidos en las mismas, guías de práctica clínica y documentos de consenso nacionales e internacionales, así como estudios de calidad en vida real. El coordinador generó las recomendaciones preliminares que fueron evaluadas y modificadas en una reunión de grupo nominal. Tras varios procesos de revisión, que incluyeron la revisión externa por parte de los miembros del GPS, se redactó el documento definitivo.

Resultados: Se presentan en este documento recomendaciones prácticas y actualizadas relativas a la toma de decisiones terapéuticas con el uso de las terapias biológicas en pacientes que pertenecen a poblaciones especiales (ancianos, edad pediátrica, mujeres embarazadas o con deseo gestacional) o que presentan comorbilidades (obesidad, artritis psoriásica, enfermedad inflamatoria intestinal, depresión, cáncer, síndrome metabólico, diabetes, hígado graso no alcohólico, enfermedad cardiovascular, insuficiencia cardíaca y enfermedad renal o neurológica). Se aborda también la gestión del riesgo con el uso de terapias biológicas, analizando los riesgos potenciales previos al tratamiento y durante el mismo, así como los acontecimientos adversos más frecuentes, todo ello desde una orientación práctica y adaptada a la práctica clínica habitual.

© 2022 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Decisions regarding the use of biologic therapies in psoriasis are influenced not only by drug- and disease-related variables such as efficacy and severity or impact, but also by patient-related factors such as age, pregnancy plans, and comorbidities.^{1,2}

This updated consensus statement incorporates a series of changes and additions with respect to previous publications on the management of special populations, comorbidities, and risk in the setting of moderate to severe psoriasis treated with biologic therapies.^{3–6}

Methods

The methodology underlying this project, an initiative of the Psoriasis Group (GPs) of the Spanish Academy of Dermatology and Venereology (AEDV), is described in Part 1 of this publication.⁷ In brief, consensus on the recommendations presented was reached using the nominal group technique supported by a scoping review and methodologic oversight.

The first step was to assign a group coordinator and then select a group of (GPs in its Spanish acronym) members with experience and knowledge of psoriasis to form the nominal group. The coordinator, with methodologic support, defined the objectives, scope, users, and sections of the consensus statement. Considering the volume of publications on the efficacy and safety of biologic therapies, including biosimilars and new-generation synthetic molecules, in moderate to severe psoriasis, it was decided to conduct a scoping review. This review was conducted by the group coordinator with the help of an expert documentalist, who designed several search strategies that included Medical Subject Heading and free-text terms for the main bibliographic databases: Medline, Embase, and the Cochrane Library. The search targeted articles published up to January 2021. The following studies were selected for review: systematic reviews, meta-analyses, randomized controlled trials (RCTs) not included in the previous 2 groups, and high-quality real-world studies. National and international clinical practice guidelines and consensus statements on the management of moderate to severe psoriasis were also reviewed.

Based on the results of the scoping review, the group coordinator drew up a series of preliminary recommendations and drafted the sections of the consensus statement, which were evaluated, discussed, and modified in a nominal group meeting. After several rounds of revision, which included external review by GPs members, the definitive statement was drawn up.

The project was conducted in accordance with the principles of the latest version of the Declaration of Helsinki on medical research involving human subjects and applicable regulatory requirements on good clinical practice.

Results

Treatment decisions in special populations.

Patients Older Than 65 Years

Cumulative experience with the use of biologic therapies in psoriasis patients aged over 65 years is limited. These patients are poorly represented in RCTs because, apart from age restrictions, they typically have a higher burden of comorbidities and/or do not meet certain requirements.

A recent systematic review summarized the results of 18 studies (3 RCT subanalyses, 5 cohort studies, and 10 case series) on the use of biologic therapies in patients with moderate to severe psoriasis older than 65 years.⁸ Overall, biologics had a similar efficacy to that reported for younger patients, although some of the studies reported an increased risk of adverse events (including serious ones) in patients older than 65 years, although the risk associated with conventional systemic therapies was even higher.^{9,10} The main findings of the studies are summarized in [Table 1](#).

The GPs considers that treatment goals for patients older than 65 years should be the same as those recommended for the general population (see Part 1 of the GPs consensus statement). The same applies to choice and use of biologic therapies, although special attention needs to be paid to risk management.

Pediatric Patients

Etanercept, adalimumab, ustekinumab, ixekizumab, and secukinumab are currently licensed for use in pediatric patients with psoriasis (see [Table 2](#)).^{29–33} The treatment goals in this setting should be identical to those established for adults. Accordingly, children should have immediate access to biologic therapies, particularly considering that conventional treatments are not approved for use in this population. Convenience issues, such as frequency and number of injections and associated pain, are important as they can influence treatment adherence.

Pregnancy, Breastfeeding, and Wish to Become Pregnant

In 2020, the GPs published a consensus statement on the management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding.² [Tables 3 and 4](#) summarize the recommended uses of biologic therapies according to the respective summaries of product characteristics (SPCs) and also provide pregnancy- and breastfeeding-related data.

Placental passage of immunoglobulin G (IgG) antibodies from mother to child occurs from the third trimester onwards via binding of the Fc region to the neonatal Fc receptor for IgG (FcRn) in the placenta.³⁸ Monoclonal antibodies, however, differ in how they are transferred across the placenta as they have different affinities for FcRn. IgG1 (adalimumab, infliximab, secukinumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab), IgG2 (brodalumab), and IgG4 (ixekizumab) probably cross in a similar fashion.^{39–42} Infliximab and adalimumab have been detected in the blood of newborns up to 6 months after birth.⁴³ Etanercept has also been reported to have lower affinity for FcRn.^{44,45} Little or no transplacental transfer has been described for certolizumab pegol, which lacks an Fc region.^{46–48}

Table 1 Efficacy and Safety of Biologic Therapies in Patients Older Than 65 Years With Moderate to Severe Psoriasis.

Drug	Study design	No.	Efficacy	Safety
IFX ¹¹	Case series	27	-Wk 12 PASI 75: 80%	-15 discontinuations (5 due to AEs)
ETN ¹²	RCT subanalysis	77	Mean PASI reduction ($P < .001$) -PASI 75: no differences with younger patients	-No differences in discontinuation or injection reaction rates compared with younger patients -Significantly more serious AEs (unrelated to ETN) in older patients
ADA ¹³	Retrospective	16	-No differences with young patients	-No differences -Discontinuations unrelated to age; OR = 0.94 (95% CI, 0.29–3.07)
ADA ¹⁴	RCT subanalysis	54	-PASI 75 ≥ 65 y: < 61% 40–64 y: 70% < 40 y: 74%	-
ETN, ADA ¹⁵	Case series	89	-Wk 156 PASI 75: ETN 83.6% PASI 75: ADA 71.4% No differences in mean PASI reduction ($P < .001$) compared with younger patients except for ETN	-26 discontinued due to AEs
SEC ¹⁶	RCT subanalysis	67	-Wk 16 (> 65 y vs. younger patients) PASI 75: 86.4% vs. 89% PASI 90: 72.7% vs. 74.3% PASI 100: 40.9% vs. 40.9% -Wk 52 (> 65 y vs. younger patients) PASI 75: 81.1% vs. 79.4% -Similar time to response	- > 65 y vs. younger patients: AEs: 14.9% vs. 8.2% Serious SEC-related AEs: 4.5% vs. 1.8% Discontinuation rate due to AEs: 7.5% vs. 1.8% Similar infection rate
UST ¹⁷	Case series	22	-Wks 28/52/100 PASI 75: 63.6%/86.4%/90.9%	-0 serious AEs -2 serious AEs
UST ¹⁸	Case series	24	-Wks 16/28/52 PASI 75: 56.5%/59.1%/60%	-0 serious AEs -2 discontinued
GUS	Case series	20	-Wks 4/28/40–44 PASI 90: 30%/65%/75% PASI 100: 10%/30%/55%	-2 discontinued
BRO ¹⁹	RCT subanalysis	224	-Wk 52 PASI 75: 94.6% PASI 100: 52.7% -Wk 120 PASI 75: 91.4% PASI 100: 56.9%	-AEs per 100 patient-years: 308.2 -Serious AEs per 100 patient-years: 13.1
ADA, UST ²⁰	Case series	27	-Wks 16/24/52 PASI 75: 76.9%/88%/90.5%	-7 discontinuations
TIL, ETN ²¹	RCT subanalysis	161	-	-Incidence TIL 100 mg/TIL 200 mg/ETN Serious AEs: 2.51/1.76/6.83 Serious infections: 3.76/2.34/6.83
RIS ^{22,23}	RCT subanalysis	64	-Wks 16/52 PASI 90: –/81.3% PASI 100: 42.2%/60.9%	-

Table 1 (Continued)

Drug	Study design	No.	Efficacy	Safety
Various drugs ^{a,24}	Case series	266	-Mean change in PASI: Wk 0: 16.5 Wk 16: 3.7 Wk 28: 1.6 Wk 52: 1.2	-Twenty-five AEs (9.4%) (infections more common) Four cancers (3 nonmelanoma skin cancers) -Discontinuation rates: Wk 16: 3% Wk 28: 5% Wk 52: 9%
Various drugs ^{b,25}	Retrospective	48	-Older vs. younger patients: more topical and fewer biologic treatments -Older patients tended to have better results with biologics than with conventional systemic treatments -No differences in improvement in S-MAPA at wk 12 compared with younger patients	-No differences in AE or infection rates with biologics compared with younger patients -Higher percentage of AEs with classic synthetic molecules compared with biologics in older patients -IFX associated with most infections and ETN with fewest in all age groups
Various drugs ^{c,26}	Case series	187	-Wk 12: PASI 75 PASI 75: ETN 64% PASI 75: ADA 65% PASI 75: IFX 93% PASI 75: UST 100%	-AEs 0.11, 0.35, 0.19, and 0.26 per patient-years with ETN, ADA, IFX, and UST -More AEs with ADA than with ETN ($P < .050$) -Two serious AEs (pneumonia with IFX and ETN)
Various drugs ^{d,27}	Retrospective	65	-Older patients treated with fewer biologics than younger patients, but percentage rose from 7.75% in 2008 to 11.7% in 2012	-Discontinuation rate (> 65 y vs. younger patients) 18.2% vs. 12% -Total AEs in patients > 65 y; HR = 1.09 (95% CI, 0.9–1.3) -Serious AEs in patients > 65 y; HR = 3.2 (95% CI, 2.0–5.1)
Various drugs ^{e,28}	Retrospective	31	-29.8% of patients on systemic treatment would not be eligible for inclusion in RCTs	-Serious AEs in patients \geq 70 y; HR = 3.4 (95% CI, 1.6–7.1)

Abbreviations: ADA, adalimumab; AEs, adverse events; BRO, brodalumab; CER, certolizumab pegol; EFA, efalizumab; ETN, etanercept; GOL, golimumab; GUS, guselkumab; HR, hazard ratio; OR, odds ratio; PASI, Psoriasis Area and Severity Index; PASI 75/90/100, 75%/90%/100% reduction in mean PASI; RCT, randomized controlled trial; S-MAPA, Simple-Measure for Assessing Psoriasis Activity; SEC, secukinumab; TIL, tildrakizumab; UST, ustekinumab.

^a ADA (n = 83), UST (n = 77), ETN (n = 54), SEC (n = 40), IFX (n = 8), GOL (n = 3), CER (n = 1).

^b IFX, ADA, ETN, UST, GOL, CER.

^c ETN (n = 83), ADA (n = 18), IFX (n = 16), EFA (n = 14), UST (n = 4).

^d ETN, IFX, ADA, EFA, UST.

^e Various biologic treatments.

Cumulative experience with the use of TNF inhibitors does not show an increased risk of teratogenesis or a negative impact on prognosis in pregnancy (including maternal infections).^{49,50} Prospective studies of certolizumab pegol in more than 1300 pregnant women did not find an increased risk of fetal malformations or death.^{51,52} Based on these findings, the European Medicines Agency approved the continued use of certolizumab pegol during pregnancy and breastfeeding when deemed clinically necessary.

The GPs recommends considering maintaining biologic therapy during the first and second trimesters of pregnancy and weighing up risks and benefits during the third trimester. Certolizumab pegol can be maintained throughout pregnancy when considered clinically necessary.

Alternatives to brodalumab, ixekizumab, secukinumab,⁵³ guselkumab, risankizumab, ustekinumab,^{41,54–56} bimekizumab, and tildrakizumab⁵⁷ in pregnant women should be sought given the scarcity of data available. If no alternatives are possible or if it is considered that one of these drugs should be maintained or is more appropriate in a given situation, the matter should be discussed and decided on with the patient following careful assessment of the risk-benefit ratio.

Decisions regarding the use of biologic therapy should take patients' wishes to become pregnant into account. Ideally, women with moderate to severe psoriasis should plan to become pregnant when they are in remission and not on medication or when they are taking the lowest

Table 2 SPC Indications and Main Results From RCTs of Biologic Drugs Approved for Psoriasis in Pediatric Patients.

Drug	SPC indications	RCT results
Etanercept ²⁹	-Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies	-Wk 12: etanercept vs. placebo PASI 75: 57% vs. 11% ($P < .001$) PASI 90: 27% vs. 7% ($P < .001$) PGA 0/1: 53% vs. 13% ($P < .001$) -Wk 36 etanercept PASI 75: 65%-68%
Adalimumab ³⁰	-Treatment of severe chronic plaque psoriasis in children and adolescents from the age of 4 y who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies	-Wk 16 adalimumab vs. methotrexate PASI 75: 58%-44% vs. 32% PhGA 0/1: 61%-41% vs. 41% -Wk 36 adalimumab Adequate response in all cases
Ustekinumab ³¹	-Treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 12 y who are inadequately controlled by, or are intolerant to, other systemic therapies and phototherapies	-Wk 12 ustekinumab (dose-dependent) vs. placebo PASI 75: 80.6%-78.4% vs. 10.8% ($P < .001$) PASI 90: 61.1%-54.1% vs. 5.4% ($P < .001$) PhGA 0/1: 69.4%-67.6% vs. 5.4% ($P < .001$) -Wk 52 ustekinumab Maintenance of PASI responses
Ixekizumab ³²	-Treatment of moderate to severe plaque psoriasis in children from the age of 6 y with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy	-Wk 12: ixekizumab vs. placebo PASI 75: 89% vs. 25% ($P < .001$) PASI 90: 78% vs. 5% ($P < .001$) PhGA 0/1: 81% vs. 11% ($P < .001$) -Wk 48 ixekizumab Maintenance of PASI responses
Secukinumab ³³	-Treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 y who are candidates for systemic therapy	-Wk 12 secukinumab (dose-dependent) vs. placebo PASI 75: 77.5%-80% vs. 14.6% ($P < .001$) PASI 90: 76.5%-72.5% vs. 2.4% ($P < .001$) IGA mod 2011: 60%-70% vs. 4.9% ($P < .001$) -Wk 52 secukinumab PASI 75: 72.2%-85% PASI 90: 75%-81.3% IGA mod 2011: 72.2%-85%

Abbreviations: IGA mod 2011, Investigator's Global Assessment modified 2011; PASI, Psoriasis Area and Severity Index; PASI 75/90/100, 75%/90%/100% reduction in mean PASI; PGA; Physician Global Assessment; PhGA, Physician Global Assessment of patient's health status; RCTs, randomized controlled trial; SPC, summary of product characteristics.

A recent phase III RCT reported good outcomes for secukinumab up to week 52³³ and the drug is licensed for use in patients older than 6 years. Guselkumab, brodalumab, tildrakizumab, certolizumab pegol, bimekizumab, and risankizumab are currently being investigated in pediatric patients. Infliximab³⁴⁻³⁶ and guselkumab³⁷ have also been studied in case series and open-label studies involving this population.

effective dose of a drug with a good safety profile in pregnancy.

Treatment Decisions in Patients With Comorbidities

The GPs considers it important to note that the presence of certain comorbidities can influence or determine choice of biologic treatment due to safety issues or potential class effects. The main findings and recommendations in this respect are summarized in Table 5.

Obesity

Overweight and obesity can reduce treatment efficacy in psoriasis. Body weight can affect the efficacy of all biologic drugs to a greater or lesser extent, and this in

turn can influence the achievement of optimal treatment goals.^{14,69,71-75,119}

A number of studies have shown that higher body weight, and obesity in particular, can reduce the efficacy of TNF inhibitors.^{14,69-71} A similar, though lesser, effect has been reported for other biologics.^{72,73} One study of ustekinumab showed that body weight, female sex, and diabetes affect drug clearance and volume of distribution.⁷⁴ A phase II RCT examining the safety and efficacy of secukinumab showed numerically higher responses in normal-weight patients compared with obese patients, although the drug was efficacious in both cases⁷⁵; similar findings were reported for brodalumab in 2 phase III RCTs.^{75,120} Treatment with ixekizumab was associated with numerically lower Psoriasis Area and Severity Index (PASI) responses (PASI 75, 90, and 100) in higher body weight categories.⁷⁶ According to the SPC for bimekizumab, administration of 320 mg every 4 weeks after week 16 could continue to improve treatment response in

Table 3 SPC Recommendations on the Use of Biologic Treatments (Including Biosimilars and New-generation Synthetic Molecules) During Pregnancy.

Drug	SPC recommendation	Other published data
Infliximab ^{49,58}	Use if benefit outweighs risk	No data showing association with teratogenicity or poor pregnancy outcomes. No evidence of harm in animals.
Adalimumab ^{49,59}	Use if benefit outweighs risk	No data showing association with teratogenicity or poor pregnancy outcomes. No evidence of harm in animals.
Etanercept ⁵⁰	Use if benefit outweighs risk	No data showing association with teratogenicity or poor pregnancy outcomes. No evidence of harm in animals.
Certolizumab pegol ^{46,47,59,60}	Use during pregnancy if clinically necessary	Results similar to in the general population.
Brodalumab ⁵⁹	Preferable to avoid use	Lack of data in humans. No evidence of harm in animals.
Ixekizumab ^{59,61}	Preferable to avoid use	Lack of data in humans. Animal studies indicate possibility of neonatal death.
Secukinumab ⁵³	Preferable to avoid use	No data showing association with teratogenicity or poor pregnancy outcomes. No evidence of harm in animals.
Bimekizumab	Preferable to avoid use	No data showing association with teratogenicity or poor pregnancy outcomes. No evidence of harm in animals.
Guselkumab ^{62,63}	Preferable to avoid use	Lack of data in humans.
Risankizumab ⁶	Preferable to avoid use	Lack of data in humans. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
Ustekinumab ^{41,54–56}	Preferable to avoid use	Lack of data in humans.
Tildrakizumab ⁵⁷	Preferable to avoid use	Lack of data in humans.

patients weighing at least 120 kg who have not achieved full skin clearance. Pooled data from 2 phase III RCTs of guselkumab showed lower numerical efficacy in patients with a higher body weight.⁷² Similar findings were described for risankizumab (pooled data from 2 phase III RCTs)²² and tildrakizumab (pooled data from 1 phase IIb RCT and 2 phase III RCTs).⁷³ Infliximab and ustekinumab doses can be adjusted to body weight. In the latter case, a 90-mg dose is recommended as ustekinumab 45 mg has shown suboptimal efficacy in patients weighing 90 to 100 kg.¹²¹

According to their respective SPCs, TNF inhibitors may lead to weight gain. The implications of this, however, should be evaluated on a case-by-case basis.

Psoriatic Arthritis

Involvement of each of the clinical domains of psoriatic arthritis (PsA) (peripheral joint disease, axial joint disease, enthesitis, dactylitis, nail psoriasis, and skin psoriasis) should be assessed in patients with concomitant psoriasis and PsA. Treatment decisions should be made in conjunction with a rheumatologist according to the severity and impact of disease in each domain.^{77,122} Several psoriasis drugs are also licensed for use in PsA: TNF inhibitors (adalimumab, infliximab, etanercept, certolizumab), interleukin (IL) 17 inhibitors (secukinumab, ixekizumab), anti-p40 monoclonal antibodies (ustekinumab), and IL-23 inhibitors (guselkumab, risankizumab).

Bimekizumab is a dual IL-17A and IL-17F inhibitor. In phase IIb RCTs, bimekizumab doses of 16 mg and 160 mg (with or without a 320-mg loading dose) had an acceptable safety profile and were associated with significant improvements in ACR50 responses ($\geq 50\%$ improvement according to

American College of Rheumatology criteria) compared with placebo.¹²³

In phase IIb trials, tildrakizumab was associated with significant improvements in joint manifestations of PsA compared with placebo.¹²⁴ Brodalumab, an IL-17RA inhibitor, was investigated in phase III trials, but these were discontinued.

At the time of writing, phase III trials examining the use of bimekizumab and tildrakizumab in the treatment of PsA are underway.

The efficacy results for different biologic drugs (including biosimilars and new-generation synthetic molecules) from phase III RCTs are summarized in Fig. 1.^{80,122}

Several meta-analyses have shown that all the biologics licensed for use in PsA are superior to placebo and do not differ significantly from each other in this setting. Overall findings from some of the studies indicate that ustekinumab may be superior to the other approved biologics.^{126,127}

Nevertheless, other factors need to be taken into account, such as differences in evaluation times, a generally faster response to TNF and IL-17 inhibitors among patients with joint disease, and additional issues that affect prescribing decisions, such as pharmacoeconomics, impact on psoriasis, and history of previous biologic failures.¹²⁸

Meta-analyses have shown that all the biologics used in PsA are similarly effective against dactylitis and enthesitis.^{129,130}

Biologic agents may delay radiographic progression of bone erosion and joint space narrowing in patients with PsA compared with placebo. Methotrexate seems to have no added effect. Previous TNF inhibitor therapy does not appear to influence the efficacy of IL inhibitors in delaying radiographic progression.¹³¹

Table 4 SPC Recommendations on the Use of Biologic Treatments (Including Biosimilars and New-generation Synthetic Molecules) During Breastfeeding.

Drug	Breastfeeding
Infliximab ⁵⁸	-Not generally detected or detected at low doses in breast milk -AEMPS: As human immunoglobulins are excreted in milk, women should not breastfeed for at least 6 months after treatment
Adalimumab ^{59,64}	-Not generally detected or detected at very low doses in breast milk; concentrations corresponding to 0.01%–1.0% of maternal serum levels detected in human milk -AEMPS: Can be used during breastfeeding
Etanercept ⁶⁵	-Not generally detected or detected at low doses in breast milk -AEMPS: Decide whether to interrupt breastfeeding or interrupt treatment with etanercept after considering the benefits of breastfeeding for the child and of treatment for the mother
Certolizumab pegol ⁶⁶	-Not generally detected or detected at low doses in breast milk -Approved by the EMA for use in breastfeeding
Brodalumab ⁵⁹	-Transfer to breast milk unknown -AEMPS: Decide whether to interrupt breastfeeding or to interrupt/not start treatment with brodalumab after considering the benefits of breastfeeding for the child and of treatment for the mother
Ixekizumab ⁵⁹	-No data on humans -AEMPS: Decide whether to interrupt breastfeeding or to interrupt treatment with ixekizumab after considering the benefits of breastfeeding for the child and of treatment for the mother
Secukinumab ⁵⁹	-Not generally detected or detected at low doses in breast milk -AEMPS: Decide whether to interrupt breastfeeding during and up to 20 weeks after treatment with secukinumab or to interrupt treatment with secukinumab after considering the benefits of breastfeeding for the child and of treatment for the mother
Bimekizumab ⁶⁷	-Transfer to breast milk unknown -AEMPS: Decide whether to interrupt breastfeeding or to interrupt/not start treatment with bimekizumab after considering the benefits of breastfeeding for the child and of treatment for the mother
Guselkumab ^{62,63}	-No data on humans -AEMPS: Decide whether to interrupt breastfeeding during treatment and up to 12 weeks after the last dose of guselkumab or to interrupt guselkumab after considering the benefits of breastfeeding for the child and of treatment for the mother
Risankizumab ⁶	-Transfer to breast milk unknown -AEMPS: Decide whether to interrupt breastfeeding or to interrupt/not start treatment with risankizumab after considering the benefits of breastfeeding for the child and of treatment for the mother
Ustekinumab ^{41,56}	-No data on humans -AEMPS: Decide whether to interrupt breastfeeding during and up to 15 weeks after treatment with ustekinumab or to interrupt ustekinumab after considering the benefits of breastfeeding for the child and of treatment for the mother
Tildrakizumab ⁶⁸	-Transfer to breast milk unknown -Negligible levels of tildrakizumab have been observed in cynomolgus monkey milk on postnatal day 28 -AEMPS: Decide whether to interrupt breastfeeding or to interrupt/not start treatment with tildrakizumab after considering the benefits of breastfeeding for the child and of treatment for the mother

Updated with permission from Belinchon et al.²

Abbreviations: AEMPS, Spanish Agency for Medicines and Medical Devices; EMA, European Medicines Agency.

Inflammatory Bowel Disease

Patients with psoriasis have an increased incidence of inflammatory bowel disease (IBD), whether Crohn disease or ulcerative colitis.⁸¹ IBD, therefore, may be an important

factor to consider when choosing a biologic. The impact of a family history of IBD in this setting is not well established.

Certolizumab pegol is licensed for use in Crohn disease, while infliximab, adalimumab, and ustekinumab can be used in both Crohn disease and ulcerative colitis; these biologics

Table 5 Summary of Impact of Main Comorbidities on the Use of Biologic Therapies and Practical GPs and SPC Recommendations.

Comorbidity	Study results	Practical recommendations
Obesity ^{14,69–76}	-Reduced efficacy with increasing body weight (especially in obese patients)	-Refer to primary care or other specialist for weight control
PsA ^{77–80}	-Variable efficacy depending on drug and domain (arthritis, enthesitis, axial joint disease, dactylitis, etc.)	-Evaluate involvement of each PsA domain -Agree on treatment strategy with rheumatologist
IBD ^{81–86}	-New-onset IBD is very uncommon with IL-17 inhibitors -RCTs with secukinumab and brodalumab in IBD were discontinued due to a lack of efficacy or worsening of disease	-Prioritize treatments other than IL-17 inhibitors -Agree on treatment strategy with gastroenterologist -Exert special caution in patients with a family history of IBD or spondyloarthritis or digestive symptoms that may be compatible with IBD
Depression ^{5,87–90}	-Depression is very common in psoriasis, especially in patients with severe disease -Some RCTs of brodalumab detected some cases of suicide in patients with a history of psychiatric disease	-Routinely assess psychological and psychiatric comorbidities and request specialized evaluation if underlying disorder detected -Weigh up risks and benefits of brodalumab in patients with a history of depression or suicidal ideation
Cancer ^{91–97}	-No evidence that the use of biologic therapies is associated with de novo or recurrent cancer	-Agree on treatment strategy with patient and oncologist
Metabolic syndrome ¹	-Very common, especially in patients with severe psoriasis -No evidence that it is affected by biologic therapies	-No specific actions required other than management by primary care or an appropriate specialist
Diabetes ^{98–103}	-Discordant results for TNF inhibitors -Inconclusive data for other biologics	-Assess whether or not to prioritize ustekinumab or IL-17 or IL-23 inhibitors in patients with advanced diabetes -No specific actions necessary at this time
Nonalcoholic fatty liver ^{102,104–108}	-Very common -TNF inhibitors have been shown to improve metabolic and liver parameters -Animal studies have shown beneficial effects for IL-17 inhibitors	-No specific actions necessary at this time
Cardiovascular disease and risk ¹⁰⁹ Heart failure ^{110,111}	-Potential beneficial effects with biologic therapies -Worsening of heart failure with TNF inhibitors, especially adalimumab and infliximab and especially in advanced stages (III/IV) -No signs of risk with other biologic therapies	-No specific actions necessary at this time -TNF inhibitors are contraindicated in patients with stage III/IV heart failure and should be used with caution in those with stage I/II disease
Kidney disease ^{112–115}	-No evidence that biologic therapies have a negative impact on kidney disease	-No specific actions currently necessary
Neurologic disease ^{116–118}	-(Low) risk of new-onset or worsening of demyelinating disease with TNF inhibitors -No evidence of risk with other biologic therapies	-TNF inhibitors are contraindicated in patients with demyelinating disease

Abbreviations: IBD, inflammatory bowel disease; IL, interleukin; PsA, psoriatic arthritis; RCT, randomized controlled trial; SPC, summary of product characteristics; TNF, tumor necrosis factor.

could thus be prioritized in patients with moderate to severe psoriasis and IBD.⁸²

Although guselkumab and risankizumab are not approved for the treatment of IBD, evidence from phase II/III RCTs suggests that they are efficacious in this setting. They may, therefore, be an acceptable option if considered appropriate for the treatment of psoriasis. Guselkumab and risankizumab have shown good results as induction and maintenance therapies in Crohn disease.⁸³ Experience with tildrakizumab in this setting is limited to expert opinions.¹³²

New-onset IBD during IL-17 inhibitor therapy is uncommon and the incidence is no higher than would be expected in psoriasis.⁸⁶ Some cases of new-onset IBD have been described in association with IL-17 inhibitors, and RCTs investigating the use of secukinumab and brodalumab in IBD were discontinued due to a lack of treatment response and, in some cases, a worsening of disease.^{6,84,85} The GPs recommends deciding on a treatment strategy in conjunction with a gastroenterologist.

Psoriatic arthritis domains	TNF inhibitors				IL-12/23 inhibitors	IL-17RA inhibitors ^c	IL-17 A/F inhibitors ^d		IL-17 A/F inhibitors ^d	IL-23p19 inhibitors		
	ADA ^a	ETN ^a	INF ^a	CER ^a	UST	BRO	SEC	IXE	BIME	GUS	TIL	RIS
Peripheral arthritis	+	+	+	+	+	+	+	+	+	+	+	+
Axial joint disease	+	+	+	+	+	¿?	+*	+*	+	+	¿?	+?
Dactylitis	+	+	+	+	+	+	+	+	+	+	-	+
Enthesitis	+	+	+	+	+	+	+	+	+	+	-	+
Nail psoriasis	+	+	+	+	+	+	+	+	+?	+	¿?	+

Figure 1 Efficacy of biologic drugs (including biosimilars and new-generation synthetic molecules) in psoriatic arthritis according to phase III randomized controlled trials.⁸⁰ TNF indicates tumor necrosis factors; IL, interleukin; ADA, adalimumab; ETN, etanercept; IFX, infliximab; CER, certolizumab pegol; UST, ustekinumab; BRO, brodalumab; SEC, secukinumab; IXE, ixekizumab; BIME, bimekizumab; GUS, guselkumab; IL, interleukin; PsA, psoriatic arthritis; RIS, risankizumab; TIL, tildrakizumab. Colors. Dark green means that the domain was the primary endpoint of a completed phase III trial designed to assess that domain; light green, that the domain was the secondary endpoint in a completed phase III trial; dark blue, that the domain is the primary endpoint in an ongoing phase III trial with phase II results available; and light blue, that the domain is a secondary endpoint in an ongoing phase III trial with phase II results available.

+ efficacious; – not efficacious; +? few data or data not published in indexed journals;?? No data available.

^a Approved for axial spondyloarthritis (ankylosing spondylitis/nonradiographic axial spondyloarthritis).¹²⁵

^b Not approved for psoriatic arthritis; phase III RCT discontinued by sponsor.

^c Not approved for psoriatic arthritis; phase III RCT underway.

Depression

Mental health comorbidities, such as anxiety, depression, or suicidal ideation and behavior are common in psoriasis, particularly in patients with more severe disease. The association between psychological and psychiatric disorders and psoriasis is bidirectional, and there may be shared pathogenic mechanisms.⁸⁷

Adalimumab, etanercept, ustekinumab, ixekizumab, and guselkumab have been shown to improve depressive symptoms associated with psoriasis in RCT settings. A number of suicides were reported in 2 of the 3 phase III RCTs of brodalumab. They involved patients with a history of psychiatric disorders or stress triggers, and no causal relationship was found between the use of brodalumab and an increased risk of suicidal ideation or behavior. The other patients with psychiatric symptoms experienced an improvement during treatment.⁸⁸ Nonetheless, the SPC indicates that it is necessary to weigh up the risks and benefits of using brodalumab in patients with a history of depression or suicidal ideation. Brodalumab should be discontinued on appearance or worsening of depressive symptoms or suicidal ideation.⁸⁹

The GPs recommends routinely evaluating psychiatric comorbidities in patients on treatment with biologics for moderate to severe psoriasis and referring them for follow-up and specialized assessment when an underlying disorder is detected.⁵

Considering the complexity of the psychosocial factors associated with psoriasis, dermatologists and health professionals should help their patients develop coping strategies to manage the effects of their disease on physical, psychological, and social well-being.^{5,90}

Cancer

Patients with psoriasis and PsA have a slightly increased risk of certain types of cancer, mostly nonmelanoma skin cancer (NMSC) and lymphoma.⁹¹

Most evidence on the use of biologic therapies in patients with psoriasis and a previous history of cancer is based on registry or case series data or theories related to the drugs' mechanisms of action. The purported association between the immune-modulating effects of biologics and an increased risk of cancer has also been questioned, as robust evidence is lacking. In addition, general recommendations on the use of biologics in patients with psoriasis and a past history of cancer cannot be made due to the sheer number of factors at play, such as type of cancer, time since diagnosis or remission (which is linked to recurrence risk), and patient-related factors such as age and smoking history. Finally, there is no evidence to date that TNF inhibitors increase the risk of cancer recurrence in other chronic inflammatory diseases, such as rheumatoid arthritis and IBD, except in patients receiving combination immunosuppression therapy.^{92,93}

The risk of de novo cancer in patients treated with biologics has been studied in numerous publications and is not free of controversy. Although an increased risk of NMSC associated with TNF inhibitors has been described in systematic reviews and observational studies, there are probably confounding factors at play, such as exposure to UV radiation or high-dose psoralen plus UV therapy.⁹⁵ Most of the studies conducted to date have not found an association with exposure to TNF inhibitors and an increased risk of incident cancer in patients with psoriasis.⁹⁷

Table 6 Considerations Regarding the Use of Biologic Therapies (Including Biosimilars and New-General Synthetic Molecules) According to Underlying Comorbidity.

Drug	IBD	Cancer	HF	DM	Obesity	Depression	KD	MS	Lupus
Infliximab	++	+/-	P/C	++	+	+	++	C	-
Adalimumab	++	+/-	P/C	++	+	++	++	C	-
Etanercept	+	+/-	P	++	+	++	++	C	-
Certolizumab pegol	++	+/-	P/C	++	+	+	++	C	-
Brodalumab	NR	+	++	?	++	P	++	+	+
Ixekizumab	P	+	++	?	++	++	++	+	+
Secukinumab	NR	+	++	+	++	?	++	+	+
Guselkumab	+	+	++	?	++	++	++	+	+
Risankizumab	+	+	++	?	++	?	++	+	+
Ustekinumab	++	+	++	+	++	++	++	+	+
Tildrakizumab	+	+	++	?	++	?	++	+	+

Abbreviations: DM, diabetes mellitus; HF, heart failure; IBD, inflammatory bowel disease; KD, kidney disease; MS, multiple sclerosis. ++ indicates treatment of choice; +, adequate use of treatment; +/- information with discordant or inconclusive results; ?, insufficient information; C, contraindicated; NR, not recommended; P, use with precaution.

A systematic review of 71 RCTs involving 23 458 patients with psoriasis, PsA, and other inflammatory disorders treated with adalimumab did not find a significant increase in the incidence of any type of cancer (0.96 cases per 100 patient-years; 95% CI, 0.65–1.36) or lymphoma (0.63; 95% CI, 0.01–3.49).⁹⁴ The authors did, however, observe an increased incidence of NMSC (1.76; 95% CI, 1.26–2.39).

A meta-analysis of 20 RCTs analyzing the use of TNF inhibitors in 6810 psoriasis patients did not find a significant increase in the short-term incidence of cancer for any of the drugs in this class.⁹⁶

Ustekinumab also does not appear to be associated with an increased risk of cancer. A subanalysis of a phase II RCT and 3 phase III RCTs found that cancer rates in patients treated with ustekinumab were similar to those observed in the general US population. Pooled data from 2 phase II RCTs involving 3117 patients with psoriasis treated with ustekinumab for up to 3 years showed a favorable safety profile.¹³³ The overall incidence rate for cancer, excluding NMSC, was 0.98 cases per 100 patient-years (95% CI, 0.74–1.29). Specific rates were 1.42 cases per 100 patient-years (95% CI, 0.52–3.09) for melanoma, 1.21 cases per 100 patient-years (95% CI, 0.66–2.04) for prostate cancer, 0.99 cases per 100 patient-years (95% CI, 0.32–2.31) for colorectal cancer, 0.62 cases of per 100 patient-years (95% CI, 0.17–1.58) for breast cancer, and 0.80 cases per 100 patient-years (95% CI, 0.10–2.91) for lymphoma. These figures are comparable to those observed for other biologics used to treat moderate to severe psoriasis.¹³⁴

Pooled results from 2 phase III RCTs and more than 1500 psoriasis patients treated with tildrakizumab showed an incidence rate of 0.6–0.7 cases of any cancer except NMSC per 100 patient-years at 5 years (dose-dependent rates). The

corresponding rate for melanoma was 0.1 cases per 100 patient-years (95% CI, 0–0.3).¹³⁵

Data from a phase III RCT of guselkumab showed a 5-year incidence rate of 0.34 cases of NMSC per 100 patient-years and 0.45 cases of other cancers per 100 patient-years.¹³⁶

Very little information is available for the other treatments.

The EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris suggests that both TNF inhibitors such as ustekinumab and IL-17 and IL-23 inhibitors can be used to treat moderate to severe psoriasis in patients with a previous history of cancer (taking into account time in remission). It is important to note that this recommendation is supported by a low level of evidence and that decisions should always be taken on a case-by-case basis.¹³⁷

In line with the EuroGuiDerm Guideline recommendation, the GPs considers that a cancer in clinical remission, or even an active cancer, does not necessarily contraindicate the use of biologic therapy. Nonetheless, in the absence of strong evidence to the contrary, decisions must be taken in conjunction with the patient's oncologist and always discussed with the patient. The decision to use a biologic agent should be taken on a case-by case basis, with consideration of the patient's informed wishes, potential effects on quality of life, and alternatives available.

Metabolic Syndrome

Metabolic comorbidities, which include obesity, diabetes, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD), are common in psoriasis, particularly in severe forms of the disease. The association is linked to a common pathogenetic mechanism (the role of inflammation in the development of

Table 7 Risk Management Before and During Biologic Treatment of Moderate to Severe Psoriasis and Most Common AEs.

Drug	Before treatment	During treatment	Most common AEs/treatment discontinuation
<p>TNF inhibitors Infliximab Adalimumab Etanercept Certolizumab pegol</p>	<p>a) Clinical aspects -Rule out active infection (including TB), cancer, heart failure, cytopenia, demyelinating disease, relevant comorbidity -Rule out recent contact with TB patients -Discuss pregnancy plans and perform pregnancy test if necessary -Ensure measures to prevent pregnancy (except in patients on certolizumab pegol) b) Additional tests -Complete blood count, biochemistry -Serology for HVA, HVB, HVC, HIV, syphilis -Chest radiograph -Mantoux TST/IGRAs c) Other actions -Pneumococcal and flu vaccines -Consider HBV vaccination - Consider recombinant zoster vaccination -Avoid live or attenuated vaccines</p>	<p>a) Clinical aspects -Onset of infections (including TB), severe cytopenia, demyelinating disease, optic neuritis, cancer -Onset or worsening of heart failure and lung disease b) Additional tests -Complete blood count and general biochemistry 4–6 mo after treatment initiation and then at intervals tailored to the patient c) Other actions -Depending on clinical course</p>	<p>-Most common AEs ($\geq 1/100$ to $< 1/10$) Infections (particularly respiratory) Leukopenia Increased lipids Headache Nausea, vomiting Elevated liver enzymes Injection site reactions Musculoskeletal pain -Consider discontinuation in following situations: Onset of cancer, demyelinating disease, optic neuritis, severe cytopenia, new or worsening interstitial lung disease, or other serious drug-related events Onset of infection (temporary discontinuation) Pregnancy or breastfeeding (except for certolizumab pegol) or surgery posing infection risk</p>
<p>IL-17 inhibitors Bimekizumab Brodalumab Ixekizumab Secukinumab</p>	<p>a) Clinical aspects -Rule out active infection (including TB), cancer, cytopenia (carefully monitor neutrophil count), relevant comorbidity -Not recommended in patients with IBD -Weigh up risks and benefits in patients with a history of depression and/or suicidal behavior or ideation (see Table 6) -Rule out recent contact with TB patients -Ensure measures to prevent pregnancy b) Additional tests (similar to those used with TNF inhibitors) b) Other actions (similar to those used with TNF inhibitors)</p>	<p>a) Clinical aspects -Onset of infections (including TB), severe cytopenia, or other drug-related events b) Additional tests -Complete blood count and general biochemistry 4–6 mo after treatment initiation and then at intervals tailored to the patient c) Other actions -Depending on clinical course</p>	<p>-Most common AEs ($\geq 1/100$ to $< 1/10$) Infections: candidiasis, flu, tinea, herpes simplex, athletes foot Headache Oropharyngeal pain Rhinorrhea Gastrointestinal disorders: diarrhea and nausea Musculoskeletal disorders General disorders: fatigue, injection site reactions, including redness, pain, itching, bruising, and bleeding -Consider discontinuation in following situations: Onset of cancer, severe cytopenia, or other serious drug-related events Onset of infection (temporary discontinuation) Pregnancy/breastfeeding, surgery</p>

Table 7 (Continued)

Drug	Before treatment	During treatment	Most common AEs/treatment discontinuation
IL-23 inhibitors Guselkumab Risankizumab Tildrakizumab	a) Clinical aspects -Rule out active infection (including TB), cancer, cytopenia, relevant comorbidity	a) Clinical aspects -Onset of infections (including TB), severe cytopenia, or other drug-related events	-Most common AEs ($\geq 1/100$ to $< 1/10$) Infections: respiratory, gastroenteritis, herpes simplex, tinea, nasopharyngitis, sinusitis Headache
IL-12/23 inhibitors Ustekinumab	Some patients with latent TB in the clinical trials investigating risankizumab did not receive specific TB treatment and did not experience reactivation; these findings, however, did not lead to changes in the recommendation for prophylaxis in the summary of product characteristics -Ensure measures to prevent pregnancy b) Additional tests (similar to those used with TNF inhibitors) c) Other actions (similar to those used with TNF inhibitors)	b) Additional tests -Complete blood count and general biochemistry 4–6 mo after treatment initiation and then at intervals tailored to the patient c) Other actions -Depending on clinical course	Diarrhea, nausea, and vomiting Joint pain, back pain, myalgia Oropharyngeal pain Pruritus Fatigue Injection site redness and pain -Consider discontinuation in following situations: Onset of cancer, severe cytopenia, or other serious drug-related events Onset of infection (temporary discontinuation) Pregnancy/breastfeeding, surgery

Abbreviations: AEs, adverse events; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IGRAs, interferon-gamma release assays; IL, interleukin; MRI, magnetic resonance imaging; TB, tuberculosis; TNF, tumor necrosis factor; TST, tuberculin skin test.

peripheral insulin resistance) and the frequent presence of unhealthy habits in patients with psoriasis.¹

The SPCs for TNF inhibitors mention the possibility of weight gain in certain cases. Nonetheless, the potential effects of prescribing these drugs to patients with metabolic comorbidities must be evaluated on a case-by-case basis. A priori, metabolic syndrome is not a contraindication for TNF inhibitor therapy in patients with moderate to severe psoriasis.

Based on the current evidence, the GPs does not consider that the presence of metabolic syndrome should influence choice of biologic.

Diabetes

Discordant results have been published on the use of TNF inhibitors in patients with glucose metabolism and insulin sensitivity. Etanercept may improve plasma glucose levels and insulin resistance,⁹⁸ and psoriasis patients on TNF inhibitor therapy have a lower risk of new-onset type 2 diabetes compared with those receiving nonbiologic treatments.⁹⁹ No significant effects were found for etanercept on insulin secretion or sensitivity after 2 weeks' treatment in a double-blind RCT involving 12 psoriasis patients with a high risk of type 2 diabetes.¹⁰⁰ The authors of another study found no significant changes in fasting glucose levels or insulin sensitivity in 9 patients with psoriasis after 12 weeks of treatment with adalimumab.¹⁰¹ A pooled analysis of phase III RCTs did not find any significant effects for secukinumab on glucose metabolism.¹⁰² Nonetheless,

patients with diabetes showed inferior responses to ustekinumab and secukinumab in a phase III RCT.¹⁰³

In brief, based on the current evidence, the presence or absence of concomitant diabetes should not influence choice of biologic. A diagnosis of advanced diabetes, however, could justify prioritizing the use of ustekinumab or IL-17 or IL-23 inhibitors.

Nonalcoholic Fatty Liver Disease

NAFLD is considered the leading cause of chronic liver disease in western countries and can progress from steatosis to different stages of inflammation, fibrosis, and cirrhosis (nonalcoholic steatohepatitis [NASH]). Numerous epidemiological studies have confirmed that NAFLD is approximately 50% more common in patients with psoriasis.¹⁰⁴ Moreover, patients with psoriasis appear to be at higher risk of progressing to advanced forms of NAFLD, while patients with NAFLD have more severe forms of psoriasis.¹⁰⁵

The pathogenic relationship between NAFLD and psoriasis is complex and probably multifactorial. Several comorbidities commonly seen in psoriasis, such as obesity, dyslipidemia, and type 2 diabetes, can also cause NAFLD, and the link appears to be a state of persistent chronic inflammation and peripheral insulin resistance.

The high prevalence of NAFLD in patients with psoriasis may influence treatment decisions. Biologics could have a favorable impact on NAFLD due to their potential effects on systemic inflammation, while TNF inhibitors have been shown to improve metabolic and liver parameters in patients

with NAFLD and psoriasis.¹³⁸ IL-17, in turn, was recently implicated in the pathogenesis of psoriasis and the pathogenesis and disease course of NAFLD.¹⁰⁶

There is little or no clinical evidence on the effects of IL-17 or IL-23 on the course of NAFLD.^{102,107,108}

Cardiovascular Disease and Risk

Patients with psoriasis have an increased risk of cardiovascular events such as myocardial infarction and cerebrovascular accident. The risk increases with disease severity and is related to both the inflammatory nature of cardiovascular (CV) disease and the coexistence of components of metabolic syndrome/CV risk factors or the presence of PsA.¹³⁹ Standard recommendations for patients with psoriasis include CV risk factor detection, monitoring, and prevention.¹

There is no evidence that any of the biologic treatments licensed for use in psoriasis have a negative impact on CV morbidity. TNF inhibitors (adalimumab in particular) and ustekinumab may even improve CV risk factors in patients with psoriasis.^{137,140–142}

In a systematic review of the effects of biologics on imaging and biomarkers of CV disease in patients with psoriasis, González-Cantero et al.¹⁴³ did not find a significant reduction in aortic vascular inflammation in patients treated with adalimumab compared with placebo at weeks 12–16. They also found no beneficial effect for adalimumab or secukinumab compared with placebo on imaging biomarkers of CV risk (aortic vascular inflammation or flow-mediated dilatation), although they did observe a reduction in aortic vascular inflammation at week 12 (but not 52) in patients treated with ustekinumab. The main reductions in blood-based cardiometabolic risk markers were observed for adalimumab (C-reactive protein, TNF, IL-6, and GlycA) and phototherapy (C-reactive protein and IL-6) compared with placebo.¹⁴³

Several observational studies using computed coronary angiography and other techniques have shown that biologic therapy has a positive effect on coronary artery plaques in patients with psoriasis, particularly those with severe forms.^{142,144}

In a prospective observational study of patients with moderate to severe psoriasis and low CV risk according to the Framingham score, biologic treatment was associated with a 6% reduction in noncalcified coronary plaque burden ($P = .005$) and an additional reduction in necrotic core ($P = .03$) at 1 year. Patients who did not receive biologic treatment, by contrast, showed slow plaque progression (change of -0.07 mm^2 vs. 0.06 mm^2 ; $P = .02$).¹⁴² A reduction in the perivascular fat attenuation index was also observed in patients with a similar profile who had been treated with biologics; no change was observed in those not treated with biologics.¹⁴²

Current evidence suggests that biologic therapies do not have a negative effect on CV comorbidity and might even have a beneficial effect, particularly in patients with low CV risk. Biologics might, therefore, improve long-term outcomes in psoriasis patients with comorbid CV disease. There is insufficient evidence, however, to support the use of biologics to treat moderate to severe psoriasis based on the

concomitant presence of cardiovascular disease, or to prioritize any one treatment over the other. These considerations might change as new evidence emerges.

Congestive Heart Failure

TNF inhibitors, in particular adalimumab and infliximab, are contraindicated in stage III/IV heart failure and should be used with caution in stages I and II.¹¹⁰ No contraindications have been established for ustekinumab or IL-17 or IL-23 inhibitors in patients with heart failure.¹¹¹

Kidney Disease

Patients with psoriasis have an increased incidence of chronic kidney disease related to the higher incidence of CV and metabolic comorbidities in this setting.¹¹² One study reported a significantly increased risk of death associated with nonhypertensive kidney disease in patients with severe psoriasis.¹¹⁴ Another cohort study also showed an increased risk of death due to kidney disease in psoriasis patients, even those with mild disease.¹¹³

There is no evidence that currently available biologic treatments have a negative impact on kidney function, and they might even be preferable to conventional drugs with potentially nephrotoxic effects, such as methotrexate and cyclosporin. Moreover, clearance of biologic drugs is not affected by kidney failure or dialysis.

Considering the above, the GPs does not consider kidney disease to be a contraindication for the use of biologic therapies in patients with moderate to severe psoriasis, and even believes that these treatments could be prioritized over nonbiologics in this setting.

Neurologic Disease

A number of treatments can be used in patients with psoriasis and demyelinating diseases, such as multiple sclerosis and Guillain-Barré syndrome. The supporting evidence, however, is weak.

Based on data published so far, IL-12/IL-23 inhibitors could be used in patients with demyelinating conditions.¹¹⁶

Table 8 Risk of Tuberculosis Reactivation in Patients With Moderate to Severe Psoriasis Treated With Biologic Drugs, Including Biosimilars.

Drug(s)	Risk of tuberculosis
TNF inhibitors	Increased risk in RCT and real-world settings ^{146,149}
Ustekinumab	Uncertain risk (cases described) in RCTs ^{134,150}
Secukinumab	No increased risk in RCTs ^{151,152}
Ixekizumab	No increased risk in RCTs ^{149,152}
Brodalumab	No increased risk in RCTs ^{149,152}
Guselkumab	No increased risk in RCTs ^{149,153}
Tildrakizumab	No increased risk in RCTs ^{149,154}
Risankizumab	No increased risk in RCTs ^{149,155}

Abbreviation: RCT, randomized clinical trial.

There are also data supporting the use of IL-17 inhibitors in multiple sclerosis, with findings showing that secukinumab might reduce lesion activity on magnetic resonance imaging.¹¹⁷

New-onset and worsening of demyelinating disease have been described in psoriasis patients treated with TNF inhibitors; although demyelinating conditions are uncommon in this setting, TNF inhibitors should be avoided in patients with active demyelination.¹¹⁸ In some cases, the effects of demyelination may remain after treatment discontinuation. Based on the current evidence, biologics from the other therapeutic groups are not contraindicated in patients with a past history of neurologic disease.

The treatment options for psoriasis according to comorbid conditions are summarized in [Table 6](#).

Risk Management in Patients on Biologic Therapy

One of the main advantages of biologics in the treatment of moderate to severe psoriasis is their overall acceptable safety profile. Certain measures, however, are necessary to ensure early detection of adverse events ([Table 7](#)).

Screening measures prior to the initiation of any biologic should be the same as those used for any systemic drug. The goal is to perform an overall evaluation of the patient’s safety profile that will enable initiation of any treatment available throughout the course of disease.

Because blood tests have low sensitivity for the detection of most adverse events associated with biologic therapies, periodic testing is only recommended when deemed necessary because of treatment issues, comorbidities, or clinical status, or when indicated in the respective SPC ([Table 7](#)).

Below is a summary of risk management considerations that should be taken into account in patients receiving biologic treatment.

Neurotoxicity

In principle, TNF inhibitors are not recommended in patients with psoriasis and multiple sclerosis because they may have a pathogenic role or worsen existing symptoms. Interruption of treatment should be considered if a patient develops neurological abnormalities or experiences worsening of an existing neurological disorder.¹⁴⁵

No cases or warnings of neurotoxicity have been described for other biologic therapies.^{116,117}

Tuberculosis

Standard recommendations for biologic therapies include screening for active or latent tuberculosis (TB) before treatment initiation. Patients should undergo a targeted history to rule out a present or past history of TB, in addition to a chest radiograph and a skin and/or serologic test before treatment initiation. If latent TB is detected, prophylaxis should be started in accordance with local guidelines and recommendations. Secondary prevention of TB, however, is not free of adverse effects.

The increased risk of TB reactivation with the use of TNF inhibitors has been widely documented.¹⁴⁶ According to a systematic review of RCTs, patients treated with IL-23 and IL-17 inhibitors did not have an increased incidence of TB

compared with the general population. Clinical trials investigating the use of risankizumab in psoriasis did not detect reactivation in a number of patients with latent TB who did not receive prophylaxis.¹⁴⁷ The SPC, however, continues to recommend TB prophylaxis in patients with latent disease.

The GPs considers that risankizumab may be an acceptable treatment for patients with latent TB when prophylaxis is contraindicated or carries a high risk. There is no experience with other drugs from the same therapeutic class (guselkumab and tildrakizumab), although they have a similar mechanism of action. Long-term real-world data on new drug classes is needed before firm recommendations can be made.

Patients with a negative TB test during screening can still develop primary TB during treatment, and general recommendations are lacking on whether and how often patients should be retested. Decisions should be taken on a case-by-case basis according to epidemiologic risk and the presence of suggestive symptoms.¹⁴⁸ The risk of TB reactivation with different biologic drugs, including biosimilars and new-generation synthetic molecules, is summarized in [Table 8](#).

Viral Hepatitis

Serologic screening for hepatitis B is common practice before initiation of a biologic treatment ([Table 9](#)). The EuroGuiDerm Guideline recommends screening for both hep-

Table 9 Interpretation of HBV Serologic Test Results.

HBsAg	Negative	Not infected or vaccinated
anti-HBc	Negative	
anti-HBs	Negative	
HBsAg	Negative	Immune due to natural infection
anti-HBc	Positive	
anti-HBs	Positive	
HBsAg	Negative	Immune due to HB vaccination
anti-HBc	Negative	
anti-HBs	Positive	
HBsAg	Positive	Acute HVB infection
anti-HBc	Positive	
anti-HBc IgM	Positive	
anti-HBs	Negative	
HBsAg	Positive	Chronic HVB infection
anti-HBc	Positive	
anti-HBc IgM	Negative	
anti-HBs	Negative	
HBsAg	Negative	Unclear interpretation with 4 possibilities:
anti-HBc	Positive	Resolved infection (most common)
anti-HBs	Negative	False-positive anti-HBc
		“Low-level” chronic infection
		Resolving acute infection

Abbreviations: antiHBc, hepatitis B core antibody; antiHBs, hepatitis B surface antibody; HbsAg, hepatitis B surface antigen; HB, hepatitis B; HBV, hepatitis B virus.

Table 10 Main Characteristics of Some of the Vaccines Available in Spain and Recommended Use During Treatment With Biologics (Including Biosimilars and Small-Molecule Drugs).

Vaccine	Microbiologic classification	Active ingredient	Recommendation
Varicella	Live attenuated Recombinant	Attenuated varicella virus, Oka strain Varicella-zoster virus glycoprotein E	Contraindicated Possible
Parotiditis, rubeola, measles	Live attenuated	Attenuated parotiditis, rubeola, and measles viruses	Contraindicated
Yellow fever	Live attenuated	Yellow fever virus, 17D-2004 strain	Contraindicated
Typhoid fever	Live attenuated	Attenuated <i>Salmonella typhi</i> , Ty21a strain	Contraindicated
	Simple polysaccharides	Simple polysaccharides of <i>Salmonella typhi</i> , vi capsular polysaccharide	Possible
Poliomyelitis	Inactivated	Inactivated polioviruses 1,2,3	Possible
Influenza	Split Subunit	Split-virus influenza vaccine	Recommended
		Superficial hemagglutinin and neuraminidase antibodies from influenza virus	Recommended
Influenza A (H1N1)	Subunit	Superficial antibodies from influenza virus	Recommended
<i>Haemophilus influenzae</i> B	Conjugate	PRP-TT	Possible
Hepatitis A	Inactivated Virosome	Inactivated hepatitis A virus	Recommended
Hepatitis B	Recombinant	Inactivated hepatitis A virus Recombinant hepatitis B surface antigen	Recommended
Human papillomavirus	Recombinant	L1 proteins from human papillomavirus	Possible
Meningococcal C	Conjugate	De-O-acetylated polysaccharides from meningococcal C virus	Possible
Pneumococcal	Simple polysaccharides	23-valent pneumococcal polysaccharides	Recommended
	Conjugate	Pneumococcal CRM197 saccharides	Recommended
	Conjugate	Protein D, pneumococcal polysaccharides	Recommended
Diphtheria	Toxoid	Adult-type diphtheria toxoid	Possible
Tetanus	Toxoid	Tetanus toxoid	Possible
Whooping cough	Toxoid	Pertussis toxoid	Possible
COVID	RNA Viral vectors	Messenger RNA Genetic material	Recommended

Abbreviation: PRP-TT, polysaccharide polyribosomal phosphate tetanus toxoid.

atitis B (hepatitis B surface antigen [HbsAg], hepatitis B surface antibody [anti-HBs], and hepatitis B core antibody [anti-HBc]) and hepatitis C before starting conventional or biologic therapy.¹³⁷ Screening for hepatitis A is not recommended (strong consensus).

Once immune status has been determined, administration of the first dose (or even a booster dose if deemed necessary) before initiation of biology therapy could be considered in HBsAg/anti-HBc-negative patients. The remaining doses can be administered safely, even in patients already

on TNF inhibitor therapy.^{156,157} Patients with positive anti-HBc and positive HBsAg should be considered as carriers of an active infection and should be referred to a hepatologist for evaluation before starting biologic treatment.

Anti-HBc-positive and HbsAg-negative patients are a more challenging group and should undergo hepatitis B virus DNA testing. If the result is negative, biologic therapy can be started, but the patient should be monitored according to local guidelines and in consultation with a hepatologist. Treatment should preferably be initiated with ustekinumab or an IL-17 or IL-23 inhibitor. No cases of hepatitis B reactivation have been described to date for ixekizumab, brodalumab, guselkumab, tildrakizumab, or risankizumab.¹⁵⁸

Patients with an active infection (HbsAg-positive) must be monitored by a hepatologist and treated with an antiviral before starting psoriasis treatment with a biologic, methotrexate, or cyclosporine.

A review of the literature on the risk of hepatitis B and C virus reactivation in patients with psoriasis treated with biologics showed a very low risk of hepatitis C virus reactivation.¹⁵⁹ There is experience with the use of etanercept, even as an adjuvant to interferon and ribavirin, in patients with psoriasis and concomitant hepatitis C infection. Compared with placebo, etanercept was associated with a higher proportion of cases without hepatitis C virus RNA and greater regression of liver fibrosis. Use of infliximab in this setting is controversial due to the risk of liver toxicity, and very little has been published on certolizumab or golimumab. Experience with ustekinumab is limited to isolated cases and the results have been controversial. Of the few patients treated with secukinumab, none of them experienced viral reactivation or worsening of transaminase levels.¹⁴⁹

Overall, cumulative experience suggests that biologics can be used to treat psoriasis in patients with hepatitis C infection, but close coordination with the patient's hepatologist is necessary, as is clinical, laboratory, and virologic follow-up. Because hepatitis C is curable, cases will probably become considerably less common in many settings. Accordingly, the risk of its interfering with psoriasis treatment is routine practice will also become less of an issue.

HIV Infection

Although experience is limited, some studies have shown that combination therapy with antiretrovirals and etanercept, infliximab, adalimumab, or ustekinumab does not cause alterations and maintains good control of HIV infection. Analysis of the prospective BIOBADADERM registry found no evidence of HIV infection reactivation in psoriasis patients treated with biologic drugs in routine clinical practice.¹⁶⁰

Although evidence is lacking, the GPs considers that patients with psoriasis and concomitant HIV infection can be treated with biologic therapy, appropriate antiviral treatment decided on in coordination with the treating infectious disease specialist, and clinical and laboratory follow-up. There is no experience with the use of anti-IL-17 or anti-IL-23

Table 11 Vaccine Recommendations From the Advisory Committee for Immunization Practices.¹⁵⁷

Vaccine	Recommendation
Influenza	-Annual vaccination
Parotiditis, rubeola, measles	-1 or 2 doses in patients born after 1957 who have lost immunity
Varicella	-Adults without data on previous disease should be given an immunity test; otherwise, administer 2 doses. A booster shot is sufficient for those who have already received 1 dose.
Herpes zoster	-1 dose for adults > 60 y
Pneumococcal	-1 dose for adults > 65 y
Diphtheria and tetanus	-Booster every 10 Y and after a high-risk wound
Human papillomavirus	-Recommended for unvaccinated women up to 26 y and unvaccinated men up to 21 y
Hepatitis A, hepatitis B, <i>Haemophilus influenzae</i> type B, and meningococcal	-As per vaccine schedule or in individual situations of risk

inhibitors in this setting, although no signs of an effect have been detected in studies of other chronic viral infections.

Vaccination

Overall, biologics have a selective immunosuppressive mechanism that does not appear to significantly interfere with antibody production, as there have been reports of well-preserved humoral responses to vaccination.¹⁶¹ The main characteristics of currently available vaccines are summarized in Table 10. Table 11 summarizes the recommendations of the Advisory Committee for Immunization Practices,¹⁵⁷ which could serve as a guide for use in routine practice.

COVID-19

Strict adherence to all COVID-19 preventive measures and public health advice is recommended. Accordingly, testing for COVID-19 is recommended in patients with psoriasis who have been in close contact with a positive case, even if they are asymptomatic.

Unless contraindicated, COVID-19 vaccination with supervision by a dermatologist is recommended for all patients with psoriasis. In certain cases, the dermatologist should (or could) provide guidance on optimal vaccination timing and regimens according to the patient's current treatment (see summary of information and recommendations in Table 12).¹⁶²

Table 12 GPs Position on COVID-19 Vaccines.¹⁶²

#	Comments/recommendations
1	Currently, there is no evidence that COVID-19 vaccination has a negative effect on the course of psoriasis.
2	Currently available vaccines are based on technologies that do not pose any risk of infection activation.
3	Currently available vaccines ARE NOT live attenuated virus vaccines, which are the only vaccines contraindicated in patients on immunosuppressive therapy.
4	Based on current information, COVID-19 vaccines have a favorable short-term safety profile and similar adverse effects to those seen in other common vaccines. The most common adverse effect is injection site pain. Other relatively common adverse effects are some tiredness or weakness, fatigue, and headache; a high fever is uncommon. These effects usually resolve within a couple of days and respond to paracetamol or nonsteroidal anti-inflammatory drugs, such as ibuprofen.
5	COVID-19 vaccines are not recommended in people with a history of allergic reactions to any of their components
6	Conventional and biologic systemic drugs are not expected to cause any additional complications in association with COVID-19 vaccines.
7	-Methotrexate and cyclosporin A decrease immune response to some vaccines. Temporary discontinuation of these drugs, with consideration of their half-lives, may be considered before and after vaccination. -Overall, there is evidence that biologic treatments for psoriasis can reduce cell-mediated but not humoral responses to vaccines. There is no evidence, however, that they reduce the protection conferred by COVID-19 vaccination. -TNF inhibitors can reduce the level of antibodies induced by certain vaccines, but they do not have a significant effect on protection conferred. -Ustekinumab, secukinumab, and ixekizumab do not reduce the immunogenicity of vaccines. There are no data on more recent drugs, although it can be assumed that they behave like the other drugs in their class. -In any case, vaccination should always be considered preferable when individualized treatment modifications cannot be made.

Abbreviation: GPs, Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

Other Infectious Diseases

Leishmaniasis is a chronic, vector-borne infectious disease caused by protozoan parasites of the genus *Leishmania* that are transmitted to humans via sandfly bites. In Europe, leishmaniasis is most prevalent in Mediterranean countries. The causative species has a significant bearing on clinical manifestations and the host's immune response determines clinical outcomes. Leishmaniasis has been described in association with several immunosuppressive drugs.

A higher prevalence of subclinical leishmaniasis has been described in patients with inflammatory rheumatic diseases under treatment with biologics compared with other immunosuppressive drugs.¹⁶³ These treatments can cause atypical leishmaniasis manifestations, such as lesions covering large areas of skin and possible mucosal involvement. A targeted history is recommended before a patient from a leishmaniasis-endemic area is started on biologic therapy.

Chagas disease in patients from endemic areas is becoming increasingly common in our setting, probably due to improved access to health care and the availability of more powerful immunosuppressive treatments. Screening of

patients at risk should thus be considered before starting immunosuppressive therapy; early treatment with benznidazole and close follow-up to prevent clinical reactivation can be administered if necessary.¹⁶⁴

Immunogenicity

Drug immunogenicity (the production of antibodies against a drug) is relatively common in patients treated with biologic agents, including biosimilars. No association with increased toxicity, however, has been demonstrated.¹⁶⁵

In some cases, drug immunogenicity can result in a diminished response to treatment, either because the antibodies produced are neutralizing (i.e., they prevent binding to the target) or because they form immune complexes and increase drug clearance. Antibodies are drug-specific and cross-react with respective biosimilars. Although they have been described for all biologics, they may interfere with the efficacy of TNF inhibitors. Antibodies against ustekinumab and IL-17 or IL-23 inhibitors have little or no clinical effect.¹⁶⁶ The prevalence of anti-drug antibodies and their effect on efficacy and safety are summarized in [Table 13](#).

Table 13 Prevalence of Antibodies to Drugs in Studies of Psoriasis.

Study	Prevalence of antibodies and neutralizing antibodies to drug	Efficacy problems	Safety problems
<i>Adalimumab</i>			
Blauvelt 2018 ¹⁶⁷	Wk 0–17: 34%	No	No
Papp 2017 ¹⁶⁸	Wk 17–51: 45%	Not analyzed	Not analyzed
Menter 2008 ¹⁶⁹	-Wk 16: 64% (14% neutralizing) -Wk 20: 60% (11% neutralizing) -Wk 52: 9%	Yes (reduced efficacy in some cases)	Not analyzed
<i>Brodalumab</i>			
Lebwohl 2015 ¹⁷⁰	-Wk 52: 2% (0% neutralizing)	No	No
<i>Certolizumab pegol</i>			
Pooled analysis of CIMPASI-1 and -2 ¹⁷¹	-Wk 48 (200 mg): 19% -Wk 48 (400 mg): 8%	Yes (reduced efficacy in some cases)	Not analyzed
<i>Etanercept</i>			
Griffiths 2017 ¹⁷²	-Wk 12: 2% (0% neutralizing)	No	No
Gerdes 2018 ¹⁷³	-Wk 12–30: 0% (0% neutralizing)	Not demonstrated	
Tyring 2007 ¹⁷⁴	-Wk 96: 18% (0% neutralizing)	No	No
<i>Guselkumab</i>			
Zhu 2019 ¹⁷⁵	-Wk 100: 9%	No	No
Langley 2018 ¹²¹	-Wk 60: 9%	Not analyzed	Not analyzed
<i>Infliximab</i>			
Reich 2005 ¹⁷⁶	-Wk 46: 22% -Wk 66: 19%	Yes (reduced efficacy in some cases)	No
<i>Ixekizumab</i>			
Reich 2018 ¹⁷⁷	-Wk 60: 17% (3.5% neutralizing)	Yes (reduced efficacy in some cases)	Not analyzed
Gordon 2016 ¹¹⁹	-Wk 12: 9%	Yes (reduced efficacy in some cases)	Not analyzed
<i>Risankizumab</i>			
SPC ⁶	-Wk 52: 24%	Yes (reduced efficacy in some cases)	Increased incidence of mild and transient local reactions
<i>Secukinumab</i>			
Reich 2017 ¹⁷⁸	-Wk 60: <0.4%	No	No
<i>Tildrakizumab</i>			
Kimball 2020 ¹⁷⁹	-Wk 52/64 (100 mg): 7% -Wk 52/64 (100 mg): 8%	Yes (reduced efficacy in some cases)	No
<i>Ustekinumab</i>			
Langley 2018 ¹²¹	-Wk 60: 15%	Not analyzed	Not analyzed
Tsai 2011 ¹⁸⁰	-Wk 36: 4%	Yes (reduced efficacy in some cases)	Not analyzed
Griffiths 2010 ¹⁸¹	-Wk 64: 4%	Not analyzed	No
Leonardi 2008 ¹⁸²	-Wk 76: 5%	Not analyzed	No
Papp 2008 ¹⁸³	-Wk 52: 5%	Yes (reduced efficacy in some cases)	

Abbreviation: SPC, summary of product characteristics.

Surgery

There is little evidence that biologic therapy in patients with moderate to severe psoriasis is associated with an increased risk of surgical infection or other complications.¹⁵⁶ Numerous factors should be taken into account in patients scheduled for elective surgery, such as other risk factors (e.g., poorly controlled diabetes or use of corticosteroids), type of surgery, and psoriasis status. Proactive measures (e.g., adjustment of dosing intervals or temporary discontinuation) should only be taken in the presence of risk factors for infection (e.g., prosthesis, cholecystectomy, cataracts, and implants). These measures are more appropriate for drugs with long administration intervals.

Final Conclusions

Data from clinical trials and real-world settings have added to the body of knowledge on the effectiveness, safety, and efficiency of biologic therapies, and highlight the importance of taking into account the different clinical situations described in this updated consensus statement.

As with all long-term immunomodulatory treatments, risk management in patients on biologic therapy should be regularly reviewed and adapted to new knowledge and new mechanisms of action. Accordingly, it is important to draw on evidence-based data to strike a balance between treatment, monitoring, and reasonable guarantees to patients.

Funding

This study was entirely funded by resources from the Spanish Academy of Dermatology and Venereology (AEDV).

Conflicts of interest

José Manuel Carrascosa has served as a principal investigator/co-investigator and/or received speaker's fees and/or participated on expert or steering committees for Abbvie, Novartis, Janssen, Lilly, Sandoz, Amgen, Almirall, BMS, Boehringer Ingelheim, Biogen, and UCB.

Laura Salgado-Boquete has served as a principal investigator/co-investigator and/or received speaker's fees and/or participated on expert or steering committees for Abbvie/Celgene, Leo Pharma, Novartis, Janssen, Lilly, Sandoz, Amgen, Almirall, UCB, Pfizer, and MSD.

Lluís Puig has served as a principal investigator/co-investigator and/or received speaker's fees and/or participated on expert committees or as a scientific consultant for Abbvie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB.

Elena del Alcázar has served as a principal investigator/co-investigator and/or received speaker's fees for Abbvie, Almirall, Amgen, Celgene, Janssen, Leo-Pharma, Lilly, Novartis, Sanofi, and UCB.

Isabel Belinchón has served as a principal investigator/co-investigator and/or received speaker's fees and/or participated on expert committees or as a

scientific consultant for Abbvie, Novartis, Janssen, Lilly, Sandoz, Amgen, Almirall, BMS, Boehringer Ingelheim, Biogen, and UCB.

Pablo de la Cueva has participated as a researcher and/or consultant and/or speaker for the following pharmaceutical companies: Abbvie, Almirall, Amgen, Astellas, Biogen, BMS, Boehringer, Celgene, Gebro, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sandoz, Sanofi, and UCB.

David Moreno has served as a principal investigator and co-investigator in clinical trials sponsored by Lilly, Novartis, Amgen, Almirall, Boehringer, and Leo-Pharma.

Juan José Andrés Lencina has served as a principal investigator/co-investigator and/or received speaker's fees and/or participated on expert committees or as a scientific consultant for Abbvie, Abbvie, Leo Pharma, Novartis, Janssen, and UCB.

Acknowledgments

The authors would like to thank all the members of the GPs for their contributions to this document: M^a Teresa Abalde Pintos, Ignacio Alonso García, María Luisa Alonso Pacheco, Alsina Gibert Mercé, Gloria Aparicio Español, Mariano Ara Martín, Susana Armesto Alonso, Antoni Azón Masoliver, Ferrán Ballezá López, Ofelia Baniandres Rodríguez, Didac Barco Nebreda, Alvaro Barranquero Fernández, Ana Batalla Cebej, Isabel Bielsa Marsol, Xavier Bordas Orpinell, Leopoldo Borrego Hernando, Rafael Botella Estrada, Jesús María Careaga Alzaga, Rafael Carmena Ramón, Gregorio Carretero Hernández, Ana María Carrizosa Esquivel, Jose Manuel Casanova Seuma, Alberto Conde Taboada, Marisol Contreras Stelys, Pablo Coto Segura, Esteban Daudén Tello, Carlos De La Torre Fraga, Rubén Del Río Gil, Aleixandre Docampo Simón, Noemí Eiris Salvado, Juan Escalas Taberner, Esther Eusebio Murillo, Jose Manuel Fernandez Armenteros, Emilia Fernandez López, M^a Luisa Fernández Díaz, Almudena Fernández Orland, Carlos Ferrándiz Foraster, Marta Ferrán Farrés, Lara Ferrándiz Pulido, Eduardo Fonseca Capdevila, Manuel Galán Gutiérrez, Francisco Javier Garcia Latasa De Aranibar, Ptableilar Garcia Muret, Vicente Garcia-patos Briones, Marta García Bustinduy, Ignacio García Doval, Rosa García Felipe, Alicia L. González Quesada, Beatriz González Sixto, Alfonso González Morán, Teresa Gárate Ayastui, Francisco José Gómez García, Jose Manuel Hernanz Hermosa, M^a Isabel Hernández García, Pedro Herranz Pinto, Enrique Herrera Ceballos, Marta Herrera Sánchez, Rafael Jesús Jiménez Puya, Enrique Jorquera Barquero, Rosario De Fátima Lafuente Urrez, Salvador V. Laguarda Porter, Mónica Larrea Garcia, M^a Del Mar Llamas Velasco, Anna López Ferrer, Jesús Luelmo Aguilar, Pablo Lázaro Ochaíta, Jose Luis López Estebaranz, María Marcellán Fernández, Amparo Marquina Vila, Eugenio Marrón Moya Servando, Trinidad Martin González, Antonio Martorell Calatayud, Francisco Javier Mataix Díaz, Almudena Mateu Puchades, Carolina Medina Gil, M^a Victoria Mendiola Fernández, Miren Josune Michelena Eceiza, Jordi Mollet Sánchez, José Carlos Moreno Giménez, Carlos Muñoz Santos, Antoni Nadal Nadal, Belén Navajas Pinedo, Jaime Notario Rosa, Francisco Peral Rubio, Narciso Perez Oliva, Celia Posada García, Josep A. Pujol Montcusi, Conrado Pujol Marco, Silvia Pérez Barrio, Amparo Pérez Ferriols, Beatriz Pérez Suárez, Trinidad Repiso Montero, Miquel

Ribera Pibernat, Raquel Rivera Díaz, Vicente Rocamora Durán, Jesús Rodero Garrido, Sabela Rodríguez Blanco, M^a del Carmen Rodríguez Cerdeira, Lourdes Rodríguez Fernández – Freire, Manuel Ángel Rodríguez Prieto, Jorge Romani De Gabriel, Alberto Romero Maté, Mónica Roncero Riesco, Cristina Rubio Flores, José Carlos Ruiz Carrascosa, Diana Patricia Ruiz Genao, Ricardo Ruiz Villaverde, Montserrat Salleras Redonnet, Jorge Santos-Juanes Jiménez, María José Seoane Pose, Patricia Serrano Grau, Estrella Simal Gil, Caridad Soria Martínez, José Luis Sánchez Carazo, Manuel Sánchez Regaña, M^a Dolores Sánchez-Aguilar Rojas, Rosa Taberner Ferrer, Lucía Tomás Aragonés, Francisco Valverde Blanco, Ricardo Valverde Garrido, Francisco Vanaclocha Sebastián, Manel Velasco Pastor, Diana Velázquez Tarjuelo, Asunción Vicente Villa, David Vidal Sarró, Jaime Vilar Alejo, Eva Vilarrasa Rull, Marta Vilavella Riu, Rosario Vives Nadal, Hugo Alberto Vázquez Veiga, Juan Ignacio Yanguas Bayona, and Ander Zulaica Garate.

References

- Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, González-Parra E, et al. Position statement for the management of comorbidities in psoriasis. *J Eur Acad Dermatol Venereol.* 2018;32:2058–73.
- Belinchon I, Velasco M, Ara-Martin M, Armesto Alonso S, Baniandres Rodriguez O, Ferrandiz Pulido L, et al. Management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding: a consensus statement. *Actas Dermosifiliogr (Engl Ed).* 2021;112:225–41.
- Dauden E, Puig L, Ferrandiz C, Sanchez-Carazo JL, Hernanz-Hermosa JM, Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. *J Eur Acad Dermatol Venereol.* 2016;30 Suppl. 2:1–18.
- Puig L, Bordas X, Carrascosa JM, Dauden E, Ferrandiz C, Hernanz JM, et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology. *Actas Dermosifiliogr.* 2009;100:277–86.
- Puig L, Carrascosa JM, Carretero G, de la Cueva P, Lafuente-Urrez RF, Belinchon I, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. *Actas Dermosifiliogr.* 2013;104:694–709.
- European Medicines Agency. Skyrizi 2021. Available from: <https://www.ema.europa.eu/en/medicines/human/summaries-opinion/skyrizi-0> [Cited 2022 Jan 2].
- Carrascosa JM, Puig L, Belinchón Romero I, Salgado-Boquete L, del Alcázar E, Andrés Lencina JJ, et al. Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Part 1. «Conceptos y manejo general de la psoriasis con terapia biológica». *Actas Dermosifiliogr.* 2022, <http://dx.doi.org/10.1016/j.ad.2021.10.003>.
- Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: a systematic review. *J Cutan Med Surg.* 2020;24:174–86.
- Munera-Campos M, Vilar-Alejo J, Rivera R, Carrascosa JM, Dauden E, Herrera-Acosta E, et al. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. *J Dermatolog Treat.* 2021:1–28.
- Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastián F, Gómez-García FJ, Herrera-Ceballos E, et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry. *J Eur Acad Dermatol Venereol.* 2015;29:156–63.
- Chiricozzi A, Pavlidis A, Dattola A, Bianchi L, Chimenti MS, Fida M, et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65. *Expert Opin Drug Saf.* 2016;15:1459–62.
- Militello G, Xia A, Stevens SR, Van Voorhees AS. Etanercept for the treatment of psoriasis in the elderly. *J Am Acad Dermatol.* 2006;55:517–9.
- Chiricozzi A, Zangrilli A, Bavetta M, Bianchi L, Chimenti S, Saraceno R. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. *J Eur Acad Dermatol Venereol.* 2017;31:304–11.
- Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. *J Am Acad Dermatol.* 2010;63:448–56.
- Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. *Dermatology.* 2012;225:312–9.
- Körber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. *Drugs Aging.* 2018;35:135–44.
- Megna M, Napolitano M, Balato N, Monfrecola G, Villani A, Ayala F, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. *Clin Exp Dermatol.* 2016;41:564–6.
- Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. *J Dermatol.* 2014;41:974–80.
- Lebwohl M, Menter A, Yamauchi P, Wu JJ, Lin T, Jacobson A. Brodalumab in patients with psoriasis ages <65 and 65 years: 120-week findings from two phase 3 studies. *J Am Acad Dermatol.* 2019;81:AB176.
- Momose M, Asahina A, Hayashi M, Yanaba K, Umezawa Y, Nakagawa H. Biologic treatments for elderly patients with psoriasis. *J Dermatol.* 2017;44:1020–3.
- van de Kerkhof PC, Dauden E, Pau-Charles I, López AS, Langley R. 13632 long-term safety of tildrakizumab in patients 65 years of age or older with moderate to severe psoriasis: Pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials. *J Am Acad Dermatol.* 2020;83:AB120.
- Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. *J Eur Acad Dermatol Venereol.* 2020;34:2830–8.
- Foley P, Strober B, Valdecantos WC, Potowala H, Zhan T, Menter A. Durable efficacy of risankizumab compared with ustekinumab across subgroups of patients with moderate-to-severe plaque psoriasis: integrated analysis of two phase 3 trials. *J Am Acad Dermatol.* 2019;81:AB49.
- Ricceri F, Bardazzi F, Chiricozzi A, Dapavo P, Ferrara F, Mugheddu C, et al. Elderly psoriatic patients under biological

- therapies: an Italian experience. *J Eur Acad Dermatol Venereol.* 2018;33:143–6.
25. Garber C, Plotnikova N, Au SC, Sorensen EP, Gottlieb A. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis. *J Drugs Dermatol.* 2015;14:846–52.
 26. Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. *Acta Derm Venereol.* 2014;94:293–7.
 27. Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gómez-García FJ, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. *J Eur Acad Dermatol Venereol.* 2015;29:858–64.
 28. Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. *Arch Dermatol.* 2012;148:463–70.
 29. Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. *J Am Acad Dermatol.* 2016;74:280–7.
 30. Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. *Lancet (Lond, Engl).* 2017;390:40–9.
 31. Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12–17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. *J Am Acad Dermatol.* 2015;73:594–603.
 32. Paller AS, Seyger MMB, Alejandro Magariños G, Bagel J, Pinter A, Cather J, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA – PEDS). *Br J Dermatol.* 2020;183:231–41.
 33. Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. *J Eur Acad Dermatol Venereol.* 2021;35:938–47.
 34. Pereira TM, Vieira AP, Fernandes JC, Antunes H, Basto AS. Anti-TNF-alpha therapy in childhood pustular psoriasis. *Dermatology.* 2006;213:350–2.
 35. Skrabl-Baumgartner A, Weger W, Salmhofer W, Jahnel J. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment. *Pediatr Dermatol.* 2015;32:e13–4.
 36. Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. *Pediatr Dermatol.* 2004;21:87–8.
 37. Kim SR, Kibbi N, Craiglow BG. Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient. *JAAD Case Rep.* 2019;5:552–4.
 38. Brown SM, Aljefri K, Waas R, Hampton P. Systemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluid. *J Dermatolog Treat.* 2018;30:1–17.
 39. Garty BZ, Ludomirsky A, Danon YL, Peter JB, Douglas SD. Placental transfer of immunoglobulin G subclasses. *Clin Diagn Lab Immunol.* 1994;1:667–9.
 40. Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. *Mol Immunol.* 2015;67 Pt A:171–82.
 41. Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R. Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn's disease. *J Crohns Colitis.* 2019;13:267–9.
 42. Owczarek W, Walecka I, Lesiak A, Czajkowski R, Reich A, Zerda I, et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. *Postepy Dermatol Alergol.* 2020;37:821–30.
 43. Esteve-Solé A, Deyà-Martínez À, Teixidó I, Ricart E, Gompertz M, Torradeflot M, et al. Immunological changes in blood of newborns exposed to anti-TNF- α during pregnancy. *Front Immunol.* 2017;8:1123.
 44. Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. *Ann Rheum Dis.* 2009;68:1793–4.
 45. Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. *Rheumatology (Oxford).* 2010;49:2225–7.
 46. Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo R-M, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. *Ann Rheum Dis.* 2018;77:228–33.
 47. Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. *J Reprod Immunol.* 2016;116:7–12.
 48. Clowse M, Fischer-Betz R, Nelson-Piercy C, Scheuerle A, Kumke T, Lauwerys B, et al. POS0022 pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol: pregnancy outcomes and confounders. *Ann Rheum Dis.* 2021;80 Suppl. 1:213.
 49. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. *World J Gastroenterol.* 2013;19:2591–602.
 50. Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Liote F, Goeb V, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. *Joint Bone Spine.* 2009;76:28–34.
 51. Clowse ME, Wolf DC, Forger F, Cush JJ, Golembesky A, Shaughnessy L, et al. Pregnancy outcomes in subjects exposed to certolizumab pegol. *J Rheumatol.* 2015;42:2270–8.
 52. Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball AB, Cush JJ, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. *Arthritis Rheumatol.* 2018;70:1399–407.
 53. Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. *Br J Dermatol.* 2018;179:1205–7.
 54. Cortes X, Borrás-Blasco J, Antequera B, Fernández-Martínez S, Castera E, Martín S, et al. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature. *J Clin Pharm Ther.* 2017;42:234–6.

55. Rocha K, Piccinin MC, Kalache LF, Reichert-Faria A, Silva de Castro CC. Pregnancy during ustekinumab treatment for severe psoriasis. *Dermatology*. 2015;231:103–4.
56. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. *Ann Rheum Dis*. 2016;75:795–810.
57. Santostefano M, Herzyk D, Montgomery D, Wolf J. Non-clinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. *Regul Toxicol Pharmacol*. 2019;108:104476.
58. Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. *J Crohns Colitis*. 2011;5:555–8.
59. Rademaker M, Agnew K, Andrews M, Armour K, Baker C, Foley P, et al. Psoriasis in those planning a family, pregnant or breastfeeding. The Australasian Psoriasis Collaboration. *Australas J Dermatol*. 2018;59:86–100.
60. Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis JD. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. *Gastroenterology*. 2012;142 Suppl. 1:S149.
61. Egeberg A, Iversen L, Kimball AB, Kelly S, Grace E, Patel H, et al. Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab. *J Dermatolog Treat*. 2021;1–7.
62. Guselkumab. Drugs and lactation database (LactMed). Bethesda (MD); 2006.
63. Sanitarios AEdMyP. Ficha técnica_Guselkumab 2017.
64. Sanitarios AEdMyP. Ficha técnica_Adalimumab 2008.
65. Ostensen M, Eigenmann GO. Etanercept in breast milk. *J Rheumatol*. 2004;31:1017–8.
66. Clowse ME, Forger F, Hwang C, Thorp J, Dolhain RJ, van Tubergen A, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. *Ann Rheum Dis*. 2017;76:1890–6.
67. European Medicines Agency. Bimzelx 2021. Available from: <https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information.es.pdf> [Cited 2022 Jan 2].
68. European Medicines Agency. Ilumetri 2021. Available from: <https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information.es.pdf> [Cited 2022 Jan 2].
69. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). *Br J Dermatol*. 2008;158:558–66.
70. Prussick R, Unnebrink K, Valdecantos WC. Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis. *J Drugs Dermatol*. 2015;14:864–8.
71. Iannone F, Lopalco G, Rigante D, Orlando I, Cantarini L, Lapadula G. Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. *Autoimmun Rev*. 2016;15:447–50.
72. Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. *Br J Dermatol*. 2018;178:132–9.
73. Poulin Y, Ramon M, Rosoph L, Weisman J, Mendelsohn AM, Parno J, et al. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2 b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis. *J Eur Acad Dermatol Venerol*. 2020;34:1500–9.
74. Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. *J Clin Pharmacol*. 2009;49:162–75.
75. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. *Br J Dermatol*. 2013;168:412–21.
76. Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis. *J Eur Acad Dermatol Venerol*. 2017;31:1196–207.
77. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis*. 2020;79:1–12.
78. Torre Alonso JC, Díaz del Campo Fontecha P, Almodóvar R, Cañete JD, Montilla Morales C, Moreno M, et al. Recomendaciones de la Sociedad Española de Reumatología sobre el tratamiento y uso de terapias sistémicas biológicas y no biológicas en artritis psoriásica. *Reumatol Clin*. 2018;14:254–68.
79. Torres T, Barcelos A, Filipe P, Fonseca JE. A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains. *Front Med (Lausanne)*. 2021;7:618163.
80. Belinchón I, Salgado-Boquete L, López-Ferrer A, Ferran M, Coto-Segura P, Rivera R, et al. El papel del dermatólogo en el diagnóstico precoz de la artritis psoriásica: recomendaciones de un grupo de expertos. *Actas Dermosifiliogr*. 2020;111:835–46.
81. Egeberg A, Mallbris L, Warren RB, Bachelez H, Gislason GH, Hansen PR, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. *Br J Dermatol*. 2016;175:487–92.
82. Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, et al. Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol*. 2018;78:383–94.
83. Grossberg LB. A case report of successful treatment of Crohn's disease and psoriasis with guselkumab. *Inflamm Bowel Dis*. 2019;25:e84–90.
84. Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. *Am J Gastroenterol*. 2016;111:1599–607.
85. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut*. 2012;61:1693–700.
86. Armstrong A, Paul C, Puig L, Boehncke WH, Freeman M, Torii H, et al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. *Dermatol Ther (Heidelb)*. 2019;10:133–50.
87. Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhatani T, et al. Depression and suicidality in psoriasis: review

- of the literature including the cytokine theory of depression. *J Eur Acad Dermatol Venereol.* 2017;31:1999–2009.
88. Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. *Br J Dermatol.* 2016;175:273–86.
 89. European Medicines Agency. *Kyntheum2020* 22 Jun 2021. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum> [Cited 2022 Jan 2].
 90. Chisholm A, Nelson PA, Pearce CJ, Littlewood AJ, Kane K, Henry AL, et al. Motivational interviewing-based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well® study. *Br J Dermatol.* 2017;176:677–86.
 91. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. *JAMA Dermatol.* 2016;152:282–90.
 92. Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy. *J Clin Gastroenterol.* 2019;53:e1–11.
 93. Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. *Gastroenterology.* 2016;151:97–109.
 94. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. *Ann Rheum Dis.* 2013;72:517–24.
 95. Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. *Br J Dermatol.* 2017;178:103–13.
 96. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. *J Am Acad Dermatol.* 2011;64:1035–50.
 97. Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. *Rheumatology (Oxf, Engl).* 2019;58:e3–42.
 98. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. *J Clin Endocrinol Metab.* 2011;96:E146–50.
 99. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. *JAMA.* 2011;305:2525–31.
 100. Martinez-Abundis E, Reynoso-von Drateln C, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. *Arch Dermatol Res.* 2007;299:461–5.
 101. Kofoed K, Clemmensen A, Mikkelsen UR, Simonsen L, Andersen O, Gniadecki R. Effects of anti-tumor necrosis factor therapy on body composition and insulin sensitivity in patients with psoriasis. *Arch Dermatol.* 2012;148:1089–91.
 102. Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. *J Eur Acad Dermatol Venereol.* 2019;34:533–41.
 103. Pinter A, Gerdes S, Papavassilis C, Reinhardt M. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. *J Dermatolog Treat.* 2019;31:769–75.
 104. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther.* 2011;34:274–85.
 105. Carrascosa JM, Bonanad C, Dauden E, Botella R, Olveira-Martin A. Psoriasis and nonalcoholic fatty liver disease. *Actas Dermosifiliogr.* 2017;108:506–14.
 106. Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. *Clin Exp Immunol.* 2011;166:281–90.
 107. Rau M, Schilling AK, Meertens J, Hering I, Weiss J, Jurowich C, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. *J Immunol.* 2016;196:97–105.
 108. Herrero-Cervera A, Vinué Á, Burks DJ, González-Navarro H. Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis. *Diabetologia.* 2019;62:2143–57.
 109. Branisteanu DE, Nicolescu AC, Branisteanu DC, Branisteanu CI, Dragoi AC, Bogdanici CM, et al. Cardiovascular comorbidities in psoriasis (Review). *Exp Ther Med.* 2022;23:152.
 110. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation.* 2003;107:3133–40.
 111. Champs B, Degboé Y, Barnetche T, Cantagrel A, Ruysse-Witrand A, Constantin A. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. *RMD Open.* 2019;5:e000763.
 112. Gonzalez-Parra E, Dauden E, Carrascosa JM, Olveira A, Botella R, Bonanad C, et al. Kidney disease and psoriasis. a new comorbidity? *Actas Dermosifiliogr.* 2016;107:823–9.
 113. Svedbom A, Dalen J, Mamolo C, Cappelleri JC, Mallbris L, Petersson IF, et al. Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study. *Acta Derm Venereol.* 2015;95:809–15.
 114. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. *Br J Dermatol.* 2010;163:586–92.
 115. Grandinetti V, Baraldi O, Comai G, Corradetti V, Aiello V, Bini C, et al. Renal dysfunction in psoriatic patients. *G Ital Nefrol.* 2020;37, 2020-vol1.
 116. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. *Lancet Neurol.* 2008;7:796–804.
 117. Havrdova E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. *J Neurol.* 2016;263:1287–95.
 118. Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. *J Dermatolog Treat.* 2013;24:38–49.

119. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. *N Engl J Med.* 2016;375:345–56.
120. Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. *Br J Dermatol.* 2020;182:880–8.
121. Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. *T Br J Dermatol.* 2018;178:114–23.
122. Ostor A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPSAKE 2 trial. *Ann Rheum Dis.* 2022;81:351–8.
123. Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. *Lancet (Lond, Engl).* 2020;395:427–40.
124. Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. *Ann Rheum Dis.* 2021;80:1147–57.
125. European Medicines Agency. Cosentyx 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_es.pdf [Cited 2022 Jan 2].
126. Ruysen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. *RMD Open.* 2020;6:e001117.
127. Mease PJ, McInnes IB, Tam LS, Eaton K, Peterson S, Schubert A, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. *Rheumatology (Oxford).* 2021;60:2109–21.
128. Marzo-Ortega H, Packham J, Pujades-Rodriguez M. ‘Too much of a good thing’: can network meta-analysis guide treatment decision-making in psoriatic arthritis? *Rheumatology (Oxford).* 2021;60:3042–4.
129. Mourad A, Gniadecki R. Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis. *J Rheumatol.* 2020;47:59–65.
130. Simons N, Degboe Y, Barnetche T, Cantagrel A, Ruysen-Witrand A, Constantin A. Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. *Clin Exp Rheumatol.* 2020;38:508–15.
131. Wu D, Li C, Zhang S, Wong P, Cao Y, Griffith JF, et al. Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis. *Rheumatology (Oxford).* 2020;59:3172–80.
132. Galluzzo M, Chiricozzi A, Cinotti E, Brunasso G, Congedo M, Esposito M, et al. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. *Expert Opin Biol Ther.* 2021;12:1–10.
133. Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. *J Am Acad Dermatol.* 2012;66:731–41.
134. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. *Br J Dermatol.* 2013;168:844–54.
135. Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Drae-los Z, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). *Br J Dermatol.* 2021;185:323–34.
136. Griffiths CEM, Papp KA, Song MXX. Maintenance of response through 5 years of continuous guselkumab treatment: results from the phase 3 VOYAGE 1 trial. In: Annual coastal dermatology symposium; October 15; E-congress. 2020.
137. Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csorgo Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: Specific clinical and comorbid situations. *J Eur Acad Dermatol Venereol.* 2021;35:281–317.
138. Schramm C, Schneider A, Marx A, Lohse AW. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). *Z Gastroenterol.* 2008;46:1369–71.
139. Parisi R, Rutter MK, Lunt M, Young HS, Symmons DPM, Griffiths CEM, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. *J Invest Dermatol.* 2015;135:2189–97.
140. Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. *Br J Dermatol.* 2013;168:749–55.
141. Gelfand JM, Shin DB, Alavi A, Torigian DA, Werner T, Papadopoulos M, et al. A phase IV, randomized, double-blind placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). *J Invest Dermatol.* 2020;140:85–93.
142. Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, Belur AD, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. *Cardiovasc Res.* 2019;115:721–8.
143. Gonzalez-Cantero A, Ortega-Quijano D, Alvarez-Diaz N, Ballester MA, Jimenez-Gomez N, Jaen P, et al. Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials. *J Invest Dermatol.* 2021;141:2402–11.
144. Choi H, Uceda DE, Dey AK, Abdelrahman KM, Aksentijevich M, Rodante JA, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective observational study. *Circ Cardiovasc Imaging.* 2020;13:e011199.
145. Honda Y, Otsuka A, Egawa G, Inoue Y, Kuzuya A, Takahashi R, et al. Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-alpha therapy in psoriatic arthritis. *Eur J Dermatol.* 2015;25:487–8.
146. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. *J Rheumatol Suppl.* 2014;91:47–55.
147. Bachelez HGK, Blauvelt A, Wu J, Sivhal R, Photowala H, Valdes J, et al. In: *Venereology JotEAOda*, editor. Short and long term safety of risankizumab in patients with moderate to severe psoriasis: an integrated analysis. Paris, France: 6th congress of the skin inflammation and psoriasis international network; 2019. p. 37–8.
148. Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using

- systemic biologic agents to treat psoriasis and psoriatic arthritis. *J Am Acad Dermatol.* 2015;73:420–8.
149. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient. *J Am Acad Dermatol.* 2019;80:43–53.
 150. Cho SI, Kang S, Kim YE, Lee JY, Jo SJ. Ustekinumab does not increase tuberculosis risk: results from a national database in South Korea. *J Am Acad Dermatol.* 2020;82:1243–5.
 151. Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. *JAMA Dermatol.* 2021;157:43–51.
 152. Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. *J Eur Acad Dermatol Venereol.* 2020;34:1449–56.
 153. Puig L, Tsai TF, Bhutani T, Uy J, Ramachandran P, Song M, et al. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. *J Eur Acad Dermatol Venereol.* 2020;34:1744–9.
 154. Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. *J Eur Acad Dermatol Venereol.* 2019;33:1676–84.
 155. Al-Janabi A, Warren RB. Update on risankizumab for the treatment of moderate to severe psoriasis. *Expert Opin Biol Ther.* 2020;20:1245–51.
 156. Plachouri K-M, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. *J Dermatolog Treat.* 2018;30:668–73.
 157. Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis. *J Am Acad Dermatol.* 2013;69:1003–13.
 158. Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. *World J Gastroenterol.* 2021;27:2312–24.
 159. Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. *J Am Acad Dermatol.* 2017;77:88–97.
 160. Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellán M, Notario J, et al. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. *J Dermatolog Treat.* 2018;30:461–5.
 161. Chiricozzi A, Gisondi P, Bellinato F, Girolomoni G. Immune response to vaccination in patients with psoriasis treated with systemic therapies. *Vaccines (Basel).* 2020;8:769.
 162. Belinchón I, Puig L, Ferrándiz L, de la Cueva P, Carrascosa JM. Recomendaciones del Grupo de Psoriasis de la AEDV sobre el manejo de la consulta de psoriasis durante la pandemia por COVID-19. *Actas Dermosifiliogr.* 2020;111:802–4.
 163. Maritati M, Trentini A, Michel G, Bellini T, Almugadam S, Hanau S, et al. Subclinical Leishmania infection in patients with rheumatic diseases under biological drugs. *Infection.* 2018;46:801–9.
 164. Salvador F, Sanchez-Montalva A, Valerio L, Serre N, Roure S, Trevino B, et al. Immunosuppression and Chagas disease; experience from a non-endemic country. *Clin Microbiol Infect.* 2015;21:854–60.
 165. Boehncke WH, Brembilla NC. Immunogenicity of biologic therapies: causes and consequences. *Expert Rev Clin Immunol.* 2018;14:513–23.
 166. Tsakok T, Rispens T, Spuls P, Nast A, Smith C, Reich K. Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. *J Eur Acad Dermatol Venereol.* 2021;35:329–37.
 167. Blauvelt A, Lacour JP, Fowler JF Jr, Weinberg JM, Gospodinov D, Schuck E, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. *Br J Dermatol.* 2018;179:623–31.
 168. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. *Br J Dermatol.* 2017;177:1562–74.
 169. Menter A, Tying SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. *J Am Acad Dermatol.* 2008;58:106–15.
 170. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. *N Engl J Med.* 2015;373:1318–28.
 171. Gottlieb AB, Blauvelt A, Taçi D, Leonardi CL, Poulin Y, Drew J, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). *J Am Acad Dermatol.* 2018;79:302–14.
 172. Griffiths CEM, Taçi D, Gerdes S, Arenberger P, Pulka G, Kingo K, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. *Br J Dermatol.* 2017;176:928–38.
 173. Gerdes S, Taçi D, Griffiths CEM, Arenberger P, Poetzl J, Wuertl G, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. *J Eur Acad Dermatol Venereol.* 2018;32:420–7.
 174. Tying S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. *Arch Dermatol.* 2007;143:719–26.
 175. Zhu Y, Marini JC, Song M, Randazzo B, Shen Y-K, Li S, et al. Immunogenicity of guselkumab is not clinically relevant in patients with moderate-to-severe plaque psoriasis. *J Invest Dermatol.* 2019;139:1830–4.
 176. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. *Lancet (Lond, Engl).* 2005;366:1367–74.
 177. Reich K, Jackson K, Ball S, Garces S, Kerr L, Chua L, et al. Ixekizumab pharmacokinetics anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis. *J Invest Dermatol.* 2018;138:2168–73.
 178. Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. *Br J Dermatol.* 2017;176:752–8.
 179. Kimball AB, Kerbusch T, Aarle F, Kulkarni P, Li Q, Blauvelt A, et al. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. *Br J Dermatol.* 2019;182:180–9.
 180. Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized,

- placebo-controlled trial in Taiwanese and Korean patients (PEARL). *J Dermatol Sci.* 2011;63:154–63.
181. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *N Engl J Med.* 2010;362:118–28.
182. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet (Lond, Engl).* 2008;371:1665–74.
183. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet (Lond, Engl).* 2008;371:1675–84.